

US009580475B2

(12) United States Patent

Ross et al.

(54) COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA

- (75) Inventors: Ted M. Ross, Port St. Lucie, FL (US); Corey J. Crevar, North Huntingdon, PA (US)
- (73) Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 161 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 14/126,550
- (22) PCT Filed: Jun. 20, 2012
- (86) PCT No.: PCT/US2012/043347
 § 371 (c)(1),
 (2), (4) Date: Dec. 16, 2013
- (87) PCT Pub. No.: WO2012/177760PCT Pub. Date: Dec. 27, 2012

(65) **Prior Publication Data**

US 2014/0127248 A1 May 8, 2014

Related U.S. Application Data

- (60) Provisional application No. 61/498,800, filed on Jun.
 20, 2011.
- (51) Int. Cl. C07K 14/005 (2006.01) A61K 39/145 (2006.01) A61K 39/12 (2006.01) A61K 39/00 (2006.01)
- (58) Field of Classification Search
 CPC C12N 2760/16134; A61K 39/145; A61K 39/12; C07K 14/005
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| 7,566,454 | B2 | 7/2009 | Lu et al. | |
|--------------|------|--------|--------------------|-------------|
| 9,309,290 | B2 * | 4/2016 | Ross | C07K 14/005 |
| 2005/0181459 | A1 | 8/2005 | Baker et al. | |
| 2008/0045472 | A1 | 2/2008 | Brahmachari et al. | |
| | | | | |

2009/0074803 A1 3/2009 Sallberg et al.

(10) Patent No.: US 9,580,475 B2

(45) **Date of Patent: *Feb. 28, 2017**

| 2009/0291472 A1 | 11/2009 | Lu et al. |
|-----------------|---------|---------------|
| 2009/0327170 A1 | 12/2009 | Donati et al. |
| 2010/0041740 A1 | 2/2010 | Wong et al. |

FOREIGN PATENT DOCUMENTS

| JP | 2004-501647 | 1/2004 |
|----|----------------|----------|
| WO | WO 2002/000885 | 1/2002 |
| WO | WO 2005/020889 | 3/2005 |
| WO | WO 2007/011904 | 1/2007 |
| WO | WO 2008/028946 | 3/2008 |
| WO | WO 2009/073330 | 6/2009 |
| WO | WO 2010/003225 | 1/2010 |
| WO | WO 2010/036948 | 4/2010 |
| WO | WO 2010/036970 | 4/2010 |
| WO | WO2010036948 | * 4/2010 |
| WO | WO 2010/115133 | 10/2010 |
| WO | WO 2011/094358 | 8/2011 |
| WO | WO 2012/036993 | 3/2012 |
| WO | WO 2013/119683 | 8/2013 |
| WO | WO 2013/122827 | 8/2013 |
| WO | WO 2013/148164 | 10/2013 |

OTHER PUBLICATIONS

Sequence alignment of SEQ ID No. 1 with UniProt database access No. A4U6Y5_9INFA by Ghedin et al on May 15, 2007.*

Sequence alignment of SEQ ID No. 1 with Published_Applications_AA_Main database in U.S. Appl. No. 14/092,371 SEQ ID No. 5 by Ross et al on Nov. 27, 2012.*

UniProt Accession No. A4U6Y5, May 15, 2007.

Weaver et al., "Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin," *PLoS ONE* 6(3):e18314, Mar. 28, 2011.

Cai et al., "A Computational Framework for Influenza Antigenic Cartography," *PLoS Comput. Biol.*, vol. 6:e1000949, 2010. Carter et al., "Complex Patterns of Human Antisera Reactivity to

Carter et al., "Complex Patterns of Human Antisera Reactivity to Novel 2009 H1N1 and Historical H1N1 Influenza Strains," *PLoS ONE* 7(7):e39435, 2012.

Ekiert et al., "Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy," *Science* 324(5924):246-251, 2009.

GenBank Accession No. ABA55715, Oct. 8, 2005.

GenBank Accession No. ABD60856.1, Mar. 2, 2006.

GenBank Accession No. ABU99095, May 1, 2008.

GenBank Accession No. ABW21677, Mar. 12, 2010.

GenBank Accession No. EU195416, Mar. 12, 2010.

Giles et al., "A Computationally Optimized Hemagglutinin Virus-Like Particle Elicits Broadly Reactive Antibodies that Protect Nonhuman Primates from H5N1 Infection," *J Infect Dis* 205(10):1562-1570, 2012.

(Continued)

Primary Examiner — Shanon A Foley

(74) Attorney, Agent, or Firm — Klarquist Sparkman, LLP

(57)

ABSTRACT

Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides and influenza virus in a subject are also provided by the present disclosure.

6 Claims, 7 Drawing Sheets

(56) **References Cited**

OTHER PUBLICATIONS

Giles et al., "A Computationally Optimized Broadly Reactive Antigen (COBRA) Based H5N1 VLP Vaccine Elicits Broadly Reactive Antibodies in Mice and Ferrets," *Vaccine*, vol. 29:3043-3054, 2011.

Giles et al., "Computationally Optimized Antigens to Overcome Influenza Viral Diversity," *Expert Review of Vaccines*, vol. 11:267-269, 2012.

Giles et al., "Antibody Breadth and Protective Efficacy are Increased by Vaccination with Computationally Optimized Hemagglutinin but not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle Vaccines," *Clin. Vaccine Immunol.*, vol. 19:128-139, 2012.

Jiang et al., "Enhanced Protective Efficacy of H5 Subtype Avian Influenza DNA Vaccine with Codon Optimized HA Gene in a pCAGGS Plasmid Vector," *Antiviral Res.*, vol. 75:234-241, 2007. Parida et al., "Computational Analysis of Proteome of H5N1 Avian Influenza Virus to Define T Cell Epitopes with Vaccine Potential," *Vaccine*, vol. 25:7530-7539, 2007.

Somvanshi et al., "Prediction of Epitopes in Hemagglutinin and Neuraminidase Proteins of Influenza A Virus H5N1 Strain: A Clue for Diagnostic and Vaccine Development," *OMICS* vol. 12:61-69, 2008.

Tang et al., "Hemagglutinin Displayed Baculovirus Protects Against Highly Pathogenic Influenza," *Vaccine*, vol. 28:6821-6831, 2010. Tang et al., Characterization of Duck H5N1 Influenza Viruses with Differing Pathogenicity in Mallard (Anas platyrhynchos) Ducks, *Avian Pathol.*, vol. 38:457-467, 2009.

Tao et al., "Virus-Like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces

Protective Immunity Against Homologous and Heterologous Strains in Mice," Viral Immunol., vol. 22:273-281, 2009.

Wang et al., "Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines," *J. Virol.*, vol. 80:11628-11637, 2006.

Chen et al., "A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses," *Proc Natl Acad Sci USA* 105(36):16538-13543, 2008. Fenimore et al., "Designing and Testing Broadly-Protective

Fenimore et al., "Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage," *PLoS ONE* 7(10):e44769, 2012.

Laddy et al., "Immunogenicity of novel consensus-based DNA vaccines against avian influenza," *Vaccine* 25:2984-2989, 2007.

Prabakaran et al., "Neutralizing Epitopes of Influenza Virus Hemagglutinin: Target for the Development of a Universal Vaccine against H5N1 Lineages," *J Virol* 84(22):11822-11830, 2010.

GenBank Accession No. ABO44123, Mar. 22, 2007.

GenBank Accession No. ABQ44416, May 16, 2007.

GenBank Accession No. ABF47748, May 8, 2006.

Pushko et al., "Recombinant H1N1 Virus-Like Particle Vaccine Elicits Protective Immunity in Ferrets Against the 2009 Pandemic H1N1 Influenza Virus," *Vaccine*, vol. 28:4771-4776, 2010.

Uniprot Accession No. A4JZ83, version 33, deposited May 3, 2011 (2 pages).

Uniprot Accession No. A5GX63, version 32, deposited May 3, 2011 (2 pages).

Uniprot Accession No. B7NZ42, version 20, deposited May 3, 2011 (2 pages).

Zhao et al., "Induction of protection of against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to *Onchocerca volvulus* activation associated protein-1 (ASP-1) adjuvant," *Vaccine*, vol. 28:7233-7240, 2010.

* cited by examiner






FIG. 2






Feb. 28, 2017

Sheet 3 of 7


US 9,580,475 B2


U.S. Patent











COMPUTATIONALLY OPTIMIZED **BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA**

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the U.S. National Stage of International Application No. PCT/US2012/043347, filed Jun. 20, 2012, published in English under PCT Article 21(2), which claims the benefit of U.S. Provisional Application No. 61/498,800, filed Jun. 20, 2011, which is herein incorporated by reference in its entirety.

FIELD

This disclosure concerns optimized influenza hemagglutinin proteins that elicit broadly reactive immune responses to H1N1 virus isolates and their use as vaccines.

BACKGROUND

Influenza virus is a member of Orthomyxoviridae family. There are three subtypes of influenza viruses, designated 25 influenza A, influenza B, and influenza C. The influenza virion contains a segmented negative-sense RNA genome, which encodes the following proteins: hemagglutinin (HA), neuraminidase (NA), matrix (M1), proton ion-channel protein (M2), nucleoprotein (NP), polymerase basic protein 1 30 (PB1), polymerase basic protein 2 (PB2), polymerase acidic protein (PA), and nonstructural protein 2 (NS2). The HA, NA, M1, and M2 are membrane associated, whereas NP, PB1, PB2, PA, and NS2 are nucleocapsid associated proteins. The M1 protein is the most abundant protein in 35 influenza particles. The HA and NA proteins are envelope glycoproteins, responsible for virus attachment and penetration of the viral particles into the cell, and the sources of the major immunodominant epitopes for virus neutralization and protective immunity. Both HA and NA proteins are 40 ence to the accompanying figures. considered the most important components for prophylactic influenza vaccines.

Each year, seasonal influenza causes over 300,000 hospitalizations and 36,000 deaths in the U.S. alone (Simonsen et al., Lancet Infect Dis 7:658-66, 2007). The emergence of the novel H1N1 influenza virus in 2009 demonstrated how quickly a new influenza pandemic can sweep across the world.

There are currently two influenza vaccine approaches licensed in the United States-the inactivated, split vaccine 50 and the live-attenuated virus vaccine. The inactivated vaccines can efficiently induce humoral immune responses but generally only poor cellular immune responses. Live virus vaccines cannot be administered to immunocompromised or pregnant patients due to their increased risk of infection. 55 Thus, a need exists for a broadly protective influenza virus vaccine.

SUMMARY

Disclosed herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of 65 consensus sequences, based on selected H1N1 viruses isolated from 1918-2011.

Provided herein are recombinant influenza HA polypeptides having an optimized amino acid sequence for eliciting a broadly reactive immune response against H1N1 influenza. In some embodiments, the HA polypeptide comprises an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, the amino acid sequence of the polypeptide comprises no more than 5, no more than 6, no more than 7, no more than 8, no more than 9 or no more than 10 amino acid substitutions relative to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:

15 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, the influenza HA polypeptide lacks the N-terminal methionine residue.

Isolated nucleic acid molecules and vectors encoding the 20 recombinant HA polypeptides are also provided by the present disclosure. Further provided are isolated cells comprising such vectors.

Also provided are influenza virus-like particles (VLPs) and fusion proteins comprising the optimized HA polypeptides disclosed herein.

Further provided are compositions that include the optimized influenza HA polypeptides, fusion proteins or VLPs disclosed herein in a pharmaceutically acceptable carrier. Methods of eliciting an immune response against influenza virus in a subject by administering the disclosed compositions, fusion proteins or VLPs is also provided by the present disclosure.

Also provided are methods of immunizing a subject against influenza virus by administering to the subject a composition comprising a VLP that contains an optimized HA polypeptide.

The foregoing and other objects, features, and advantages of the disclosure will become more apparent from the following detailed description, which proceeds with refer-

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of the process used to generate an 45 H1N1 HA consensus sequence according to Method 1.

FIG. 2 is a schematic of the process used to generate an H1N1 HA consensus sequence according to Method 2.

FIG. 3 is a schematic of the process used to generate an H1N1 HA consensus sequence according to Method 4.

FIG. 4 is a schematic of the process used to generate an H1N1 HA consensus sequence according to Method 5.

FIG. 5 is a schematic of the process used to generate an H1N1 HA consensus sequence according to Method 6.

FIG. 6 is a graph showing hemagglutination-inhibition (HAI) serum antibody titers induced by COBRA H1N1 infection of mice. HAI serum antibody titers were determined in mice infected with COBRA H1N1 influenza VLPs (COBRA Method 1). Antisera were tested against the seasonal H1N1 influenza virus, A/New Calcdonia/20/1999. The 60 results are represented as the log 2 transformed geometric mean titer (±S.E.M.) from antisera collected at weeks 3, 5, 8 and 12 post-infection.

FIG. 7 is Western blot showing expression of COBRA HA protein (Method 1 consensus sequence). COBRA H1N1 HA was translated in vitro and the cell culture lysates were analyzed by SDS-PAGE and Western blot. Lane 1, A/New Calcdonia/20/1999 virus; Lane 2, H1N1 COBRA secreted

HA; Lane 3, H1N1 COBRA 5 µg VLP; Lane 4, COBRA 10 µg VLP. The COBRA HA (lane 2) migrates at its expected molecular weight confirming expression of the synthetic protein.

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter 10 code for amino acids, as defined in 37 C.F.R. 1.822. Only one stand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. The Sequence Listing is submitted as an ASCII text file, created on Dec. 11, 2013, 67.6 KB, which is incorporated by reference herein. In the accompanying sequence listing:

SEQ ID NOs: 1-11 are the amino acid sequences of optimized H1N1 HA proteins.

SEQ ID NO: 12 is a consensus amino acid sequence of the 20 optimized H1N1 HA proteins.

SEQ ID NO: 13 is the nucleic acid sequence of a codon-optimized H1N1 HA.

DETAILED DESCRIPTION

I. Abbreviations

COBRA: computationally optimized broadly reactive antigen 30

HA: hemagglutinin HAI: hemagglutination inhibition

HRP: horseradish peroxidase

M1: matrix protein 1

NA: neuraminidase

PFU: plaque form unit

VLP: virus-like particle

II. Terms and Methods

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of 45 Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:

Adjuvant: A substance or vehicle that non-specifically enhances the immune response to an antigen. Adjuvants can 55 include a suspension of minerals (alum, aluminum hydroxide, or phosphate) on which antigen is adsorbed; or waterin-oil emulsion in which antigen solution is emulsified in mineral oil (for example, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Fre- 60 und's complete adjuvant) to further enhance antigenicity. Immunostimulatory oligonucleotides (such as those including a CpG motif) can also be used as adjuvants (for example, see U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218, 371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). 65 Adjuvants also include biological molecules, such as costimulatory molecules. Exemplary biological adjuvants

include IL-2, RANTES, GM-CSF, TNF-a, IFN-y, G-CSF, LFA-3, CD72, B7-1, B7-2, OX-40L and 41 BBL.

Administer: As used herein, administering a composition to a subject means to give, apply or bring the composition into contact with the subject. Administration can be accomplished by any of a number of routes, such as, for example, topical, oral, subcutaneous, intramuscular, intraperitoneal, intravenous, intrathecal and intradermal.

Antibody: An immunoglobulin molecule produced by B lymphoid cells with a specific amino acid sequence. Antibodies are evoked in humans or other animals by a specific antigen (immunogen). Antibodies are characterized by reacting specifically with the antigen in some demonstrable way, antibody and antigen each being defined in terms of the other. "Eliciting an antibody response" refers to the ability of an antigen or other molecule to induce the production of antibodies.

Antigen: A compound, composition, or substance that can stimulate the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens. In some embodiments of the disclosed compositions and methods, the anti-25 gen is an influenza HA protein.

Codon-optimized: A "codon-optimized" nucleic acid refers to a nucleic acid sequence that has been altered such that the codons are optimal for expression in a particular system (such as a particular species of group of species). For example, a nucleic acid sequence can be optimized for expression in mammalian cells. Codon optimization does not alter the amino acid sequence of the encoded protein.

Fusion protein: A protein generated by expression of a nucleic acid sequence engineered from nucleic acid 35 sequences encoding at least a portion of two different (heterologous) proteins. To create a fusion protein, the nucleic acid sequences must be in the same reading frame and contain to internal stop codons. For example, a fusion protein includes an influenza HA fused to a heterologous protein.

Hemagglutinin (HA): An influenza virus surface glycoprotein. HA mediates binding of the virus particle to a host cells and subsequent entry of the virus into the host cell. The nucleotide and amino acid sequences of numerous influenza HA proteins are known in the art and are publically available, such as those deposited with GenBank. HA (along with NA) is one of the two major influenza virus antigenic determinants.

Immune response: A response of a cell of the immune system, such as a B-cell, T-cell, macrophage or polymorphonucleocyte, to a stimulus such as an antigen or vaccine. An immune response can include any cell of the body involved in a host defense response, including for example, an epithelial cell that secretes an interferon or a cytokine. An immune response includes, but is not limited to, an innate immune response or inflammation. As used herein, a protective immune response refers to an immune response that protects a subject from infection (prevents infection or prevents the development of disease associated with infection). Methods of measuring immune responses are well known in the art and include, for example, measuring proliferation and/or activity of lymphocytes (such as B or T cells), secretion of cytokines or chemokines, inflammation, antibody production and the like.

Immunogen: A compound, composition, or substance which is capable, under appropriate conditions, of stimulating an immune response, such as the production of antibod-

ies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal. As used herein, an "immunogenic composition" is a composition comprising an immunogen (such as an HA polypeptide).

Immunize: To render a subject protected from an infec- 5 tious disease, such as by vaccination.

Influenza virus: A segmented negative-strand RNA virus that belongs to the Orthomyxoviridae family. There are three types of Influenza viruses, A, B and C. Influenza A viruses infect a wide variety of birds and mammals, including 10 humans, horses, marine mammals, pigs, ferrets, and chickens. In animals, most influenza A viruses cause mild localized infections of the respiratory and intestinal tract. However, highly pathogenic influenza A strains, such as H5N1, cause systemic infections in poultry in which mortality may 15 reach 100%. In 2009, H1N1 influenza was the most common cause of human influenza. A new strain of swine-origin H1N1 emerged in 2009 and was declared pandemic by the World Health Organization. This strain was referred to as "swine flu." H1N1 influenza A viruses were also responsible 20 for the Spanish flu pandemic in 1918, the Fort Dix outbreak in 1976, and the Russian flu epidemic in 1977-1978.

Isolated: An "isolated" biological component (such as a nucleic acid, protein or virus) has been substantially separated or purified away from other biological components 25 (such as cell debris, or other proteins or nucleic acids). Biological components that have been "isolated" include those components purified by standard purification methods. The term also embraces recombinant nucleic acids, proteins or viruses (or VLPs), as well as chemically synthesized 30 nucleic acids or peptides.

Linker: One or more amino acids that serve as a spacer between two polypeptides of a fusion protein.

Matrix (M1) protein: An influenza virus structural protein found within the viral envelope. M1 is thought to function 35 in assembly and budding.

Neuraminidase (NA): An influenza virus membrane glycoprotein. NA is involved in the destruction of the cellular receptor for the viral HA by cleaving terminal sialic acid residues from carbohydrate moieties on the surfaces of 40 infected cells. NA also cleaves sialic acid residues from viral proteins, preventing aggregation of viruses. NA (along with HA) is one of the two major influenza virus antigenic determinants.

Operably linked: A first nucleic acid sequence is operably 45 linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two proteincoding regions, in the same reading frame.

Optimized influenza HA protein: As used herein, "optimized influenza HA protein" refers to the HA protein 55 consensus sequence generated by sequence alignments of selected H1N1 influenza viruses isolated between 1918 and 2011 (as described in Example 1 below). The nucleotide sequences encoding optimized HA proteins were (or can be) further optimized for expression in mammalian cells via 60 codon-optimization and RNA optimization (such as to increase RNA stability). Optimized influenza HA proteins disclosed herein (and set forth herein as SEQ ID NOs: 1-11) are also referred to as "COBRA" sequences. Optimized HA polypeptides are designed to elicit broadly reactive immune 65 responses in a subject. In the context of the present disclosure, "broadly reactive" means the protein sequence elicits 6

an immune response in a subject that is sufficient to inhibit, neutralize or prevent infection of a broad range of influenza viruses (such as most or all influenza viruses within a specific subtype). In some instances, the optimized influenza HA protein is capable of eliciting an immune response, such as a protective immune response, against most or all H1N1 influenza virus isolates.

Outbreak: As used herein, an influenza virus "outbreak" refers to a collection of virus isolates from within a single country in a given year.

Pharmaceutically acceptable vehicles: The pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compositions, such as one or more influenza vaccines, and additional pharmaceutical agents.

In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional nontoxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term "residue" or "amino acid residue" includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide.

Conservative amino acid substitutions are those substitutions that, when made, least interfere with the properties of the original protein, that is, the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. Examples of conservative substitutions are shown below.

| Original Residue | Conservative Substitutions |
|------------------|----------------------------|
| Ala | Ser |
| Arg | Lys |
| Asn | Gln, His |
| Asp | Glu |
| Cys | Ser |
| Gln | Asn |
| Glu | Asp |
| His | Asn; Gln |
| Ile | Leu, Val |
| Leu | Ile; Val |
| Lys | Arg; Gln; Glu |
| Met | Leu; Ile |
| Phe | Met; Leu; Tyr |

| -continued | 1 |
|------------|---|
| commute | ٠ |

| Original Residue | Conservative Substitutions |
|------------------|----------------------------|
| Ser | Thr |
| Гhr | Ser |
| Ггр | Tyr |
| Tyr | Trp; Phe |
| Val | Ile; Leu |

Conservative substitutions generally maintain (a) the 10 structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

15 The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, for example, seryl or threonyl, is substituted for (or by) a hydrophobic residue, for example, leucyl, 20 isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, for example, lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, for example, glutamyl or aspartyl; 25 or (d) a residue having a bulky side chain, for example, phenylalanine, is substituted for (or by) one not having a side chain, for example, glycine.

Preventing, treating or ameliorating a disease: "Preventing" a disease refers to inhibiting the full development of a 30 disease. "Treating" refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. "Ameliorating" refers to the reduction in the number or severity of signs or symptoms of a disease.

Promoter: A promoter is an array of nucleic acid control sequences which direct transcription of a nucleic acid. A promoter includes necessary nucleic acid sequences near the start site of transcription. A promoter also optionally 40 includes distal enhancer or repressor elements. A "constitutive promoter" is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an "inducible promoter" is regulated by an external signal or molecule (for example, a 45 transcription factor). In some embodiments herein, the promoter is a CMV promoter.

Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide, protein, virus, VLP or other 50 active compound is one that is isolated in whole or in part from naturally associated proteins and other contaminants. In certain embodiments, the term "substantially purified" refers to a peptide, protein, virus, VLP or other active compound that has been isolated from a cell, cell culture 55 of stimulating an immune response, administered for the medium, or other crude preparation and subjected to fractionation to remove various components of the initial preparation, such as proteins, cellular debris, and other components.

Recombinant: A recombinant nucleic acid, protein, virus 60 or VLP is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial 65 manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques.

Sequence identity: The similarity between amino acid or nucleic acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or variants of a given gene or protein will possess a relatively high degree of sequence identity when aligned using standard methods.

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci.

U.S.A. 85:2444, 1988; Higgins and Sharp, Gene 73:237-244, 1988; Higgins and Sharp, CABIOS 5:151-153, 1989; Corpet et al., Nucleic Acids Research 16:10881-10890, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988. Altschul et al., Nature Genet. 6:119-129, 1994.

The NCBI Basic Local Alignment Search Tool (BLASTTM) (Altschul et al., J. Mol. Biol. 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx.

Subject: Living multi-cellular vertebrate organisms, a category that includes both human and non-human mammals, such as non-human primates.

Therapeutically effective amount: A quantity of a specified agent sufficient to achieve a desired effect in a subject being treated with that agent. For example, this may be the amount of an influenza virus vaccine useful for eliciting an immune response in a subject and/or for preventing infection or disease caused by influenza virus. Ideally, in the context of the present disclosure, a therapeutically effective amount of an influenza vaccine is an amount sufficient to increase resistance to, prevent, ameliorate, and/or treat infection caused by influenza virus in a subject without causing a substantial cytotoxic effect in the subject. The effective amount of an influenza vaccine useful for increasing resistance to, preventing, ameliorating, and/or treating infection in a subject will be dependent on, for example, the subject being treated, the manner of administration of the therapeutic composition and other factors.

Transformed: A transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Vaccine: A preparation of immunogenic material capable prevention, amelioration, or treatment of disease, such as an infectious disease. The immunogenic material may include, for example, attenuated or killed microorganisms (such as attenuated viruses), or antigenic proteins, peptides or DNA derived from them. Vaccines may elicit both prophylactic (preventative) and therapeutic responses. Methods of administration vary according to the vaccine, but may include inoculation, ingestion, inhalation or other forms of administration. Inoculations can be delivered by any of a number of routes, including parenteral, such as intravenous, subcutaneous or intramuscular. Vaccines may be administered with an adjuvant to boost the immune response.

Vector: A vector is a nucleic acid molecule allowing insertion of foreign nucleic acid without disrupting the ability of the vector to replicate and/or integrate in a host cell. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. 5 An insertional vector is capable of inserting itself into a host nucleic acid. A vector can also include one or more selectable marker genes and other genetic elements. An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of an 10 inserted gene or genes. In some embodiments of the present disclosure, the vector encodes an influenza HA, NA or M1 protein. In some embodiments, the vector is the pTR600 expression vector (U.S. Patent Application Publication No. 2002/0106798; Ross et al., Nat. Immunol. 1(2):102-103, 15 2000; Green et al., Vaccine 20:242-248, 2001).

Virus-like particle (VLP): Virus particles made up of one of more viral structural proteins, but lacking the viral genome. Because VLPs lack a viral genome, they are non-infectious. In addition, VLPs can often be produced by 20 heterologous expression and can be easily purified. Most VLPs comprise at least a viral core protein that drives budding and release of particles from a host cell. One example of such a core protein is influenza M1. In some embodiments herein, an influenza VLP comprises the HA, 25 NA and/or M1 proteins. Influenza VLPs can be produced by transfection of host cells with plasmids encoding the HA and NA proteins, and optionally the M1 protein. After incubation of the transfected cells for an appropriate time to allow for protein expression (such as for approximately 72 hours), 30 VLPs can be isolated from cell culture supernatants. Example 2 provides an exemplary protocol for purifying influenza VLPs from cell supernatants. In this example, VLPs are isolated by low speed centrifugation (to remove cell debris), vacuum filtration and ultracentrifugation 35 through 20% glycerol. Other methods of producing influenza VLPs are known in the art (see, for example, U.S. Patent Application Publication Nos. 2006/0263804; 2008/ 0031895; 2010/0166769; and 2010/0239610).

Unless otherwise explained, all technical and scientific 40 terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include 45 "and" unless the context clearly indicates otherwise. Hence "comprising A or B" means including A, or B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and 50 are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other refer- 55 ences mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

III. Overview of Several Embodiments

Disclosed herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive 65 immune response to H1N1 influenza. The optimized HA polypeptides were developed through a series of HA protein

alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. The methods used to generate the 11 HA consensus sequences are described in Example 1 and FIGS. **1-5**. The amino acid sequences of the 11 consensus HA polypeptides are set forth herein as SEQ ID NOs: 1-11. In addition, an amino acid consensus sequence of SEQ ID NOs: 1-11 is provided herein as SEQ ID NO: 12.

Provided herein are recombinant influenza HA polypeptides having an optimized amino acid sequence for eliciting a broadly reactive immune response against H1N1 influenza. In some embodiments, the HA polypeptide comprises an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. In other embodiments, the amino acid sequence of the polypeptide comprises no more than 5, no more than 6, no more than 7, no more than 8, no more than 9 or no more than 10 amino acid substitutions relative to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.

In particular embodiments, provided is a recombinant influenza HA polypeptide comprising an amino acid sequence at least 99% identical to SEQ ID NO: 1; at least 99.2% identical to SEQ ID NO: 2; at least 99% identical to SEQ ID NO: 3; at least 99% identical to SEQ ID NO: 4; at least 98% or at least 99% identical to SEQ ID NO: 5; at least 99% identical to SEQ ID NO: 6; at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 7; at least 98% or at least 99% identical to SEQ ID NO: 7; at least 99% identical to SEQ ID NO: 8; comprising SEQ ID NO: 9; at least 99% identical to SEQ ID NO: 10; or at least 99% identical to SEQ ID NO: 11.

In other particular embodiments, the recombinant influenza HA polypeptide comprises an amino acid sequence at least 99% identical to residues 2-566 of SEQ ID NO: 1; at least 99.2% identical to residues 2-566 of SEQ ID NO: 2; at least 99% identical to residues 2-566 of SEQ ID NO: 3; at least 99% identical to residues 2-566 of SEQ ID NO: 4; at least 98% or at least 99% identical to residues 2-566 of SEQ ID NO: 5; at least 99% identical to residues 2-566 of SEQ ID NO: 6; at least 97%, at least 98% or at least 99% identical to residues 2-566 of SEQ ID NO: 7; at least 99% identical to residues 2-566 of SEQ ID NO: 7; at least 99% identical to residues 2-566 of SEQ ID NO: 8; comprising residues 2-566 of SEQ ID NO: 9; at least 99% identical to residues 2-566 of SEQ ID NO: 10; or at least 99% identical to residues 2-566 of SEQ ID NO: 11.

In other embodiments, the amino acid sequence of the HA polypeptide comprises (i) no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 1; (ii) no more than 4, no more than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 2; (iii) no more than 6, no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 3; (iv) no more than 8, no more than 7, no more than 6, no more than 5, nor more than 4, no more 60 than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 4; (v) no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 5; (vi) no more than 8, no more than 7, no more than 6, no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 1 amino acid

substitution(s) relative to SEQ ID NO: 6; (vii) no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 1 amino acid substitution(s) relative to SEQ ID NO: 7; (viii) no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, nor more than 4, no more than 3, no more than 2 or no more than 4, no more than 3, no more than 5, nor more than 4, no more than 3, no more than 6, no more than 1 amino acid substitution(s) relative to SEQ ID NO: 8; (ix) no more than 8, no more than 7, no more than 6, no more than 5, nor more than 1 amino acid substitution(s) relative to SEQ ID NO: 10; or (x) no more than 5, nor more than 1 amino acid substitution(s) relative to SEQ ID NO: 10; or (x) no more than 1 amino acid substitution(s) relative to SEQ ID NO: 10; or (x) no more than 1 amino acid substitution(s) relative to SEQ ID NO: 10; or (x) no more than 1 amino acid substitution(s) relative to SEQ ID NO: 11.

In some examples, the influenza HA polypeptide comprises or consists of the amino acid sequence of residues 2-566 of SEQ ID NO: 1, residues 2-566 of SEQ ID NO: 2, residues 2-566 of SEQ ID NO: 3, residues 2-566 of SEQ ID NO: 4, residues 2-566 of SEQ ID NO: 5, residues 2-566 of 20 SEQ ID NO: 6, residues 2-566 of SEQ ID NO: 7, residues 2-566 of SEQ ID NO: 8, residues 2-566 of SEQ ID NO: 9, residues 2-566 of SEQ ID NO: 10 or residues 2-566 of SEQ ID NO: 11.

In other examples, the recombinant HA polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.

In another example, the recombinant HA polypeptide 30 comprises or consists of the amino acid sequence of SEQ ID NO: 12. In yet another example, the recombinant HA polypeptide comprises or consists of the amino acid sequence of residues 2-566 of SEQ ID NO: 12.

Further provided are isolated nucleic acid molecules 35 encoding the recombinant HA polypeptides disclosed herein. In some embodiments, the nucleic acid molecule is codon-optimized for expression in mammalian cells. The nucleic acid molecule is optionally further optimized for RNA stability. In some embodiments, the sequence of the 40 nucleic acid molecule is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 13. In particular examples, the sequence of the nucleic acid molecule comprises or consists of SEQ ID NO: 13.

Vectors comprising the nucleic acid molecules encoding 45 recombinant HA polypeptides are also provided by the present disclosure. The vector can be any suitable vector for expression of the HA polypeptide, such as a mammalian expression vector. In particular examples, the vector is the pTR600 expression vector (U.S. Patent Application Publi- 50 cation No. 2002/0106798, herein incorporated by reference; Ross et al., *Nat. Immunol.* 1(2):102-103, 2000; Green et al., *Vaccine* 20:242-248, 2001).

In some examples, the vector includes a promoter operably linked to the nucleic acid sequence encoding the HA 55 polypeptide. In particular examples, the promoter is a CMV promoter.

Also provided are isolated cells comprising the disclosed vectors. In some cases, the cell is any suitable cell type for production and expression of VLPs, such as a mammalian 60 cell.

Further provided are influenza VLPs comprising an optimized HA polypeptide disclosed herein. The influenza VLPs can further include any additional influenza proteins necessary to form the virus particle. In some embodiments, the 65 influenza VLPs further include influenza neuraminidase (NA) protein, influenza matrix (M1) protein, or both. 12

Also provided are influenza VLPs comprising an influenza HA polypeptide disclosed herein, produced by transfecting a host cell with a vector encoding the HA polypeptide, a vector encoding an influenza NA protein and a vector encoding an influenza M1 protein under conditions sufficient to allow for expression of the HA, M1 and NA proteins.

Fusion proteins comprising an optimized influenza HA polypeptide are further provided by the present disclosure.

Also provided herein are compositions comprising an optimized influenza HA protein as disclosed herein, or a fusion protein or VLP comprising the optimized influenza HA protein. In some embodiments, the compositions further comprise a pharmaceutically acceptable carrier and/or an adjuvant. For example, the adjuvant can be alum, Freund's complete adjuvant, a biological adjuvant or immunostimulatory oligonucleotides (such as CpG oligonucleotides).

Further provided is a method of eliciting an immune response to influenza virus in a subject by administering an optimized influenza HA protein, fusion proteins containing an optimized influenza HA, VLPs containing an optimized influenza HA, or compositions thereof, as disclosed herein. In some embodiments, the influenza virus is an H1N1 influenza virus. In some embodiments, the HA protein, HA fusion protein or VLP can be administered using any suitable route of administration, such as, for example, intramuscular. In some embodiments, the HA protein, fusion protein or VLP is administered as a composition further comprising a pharmaceutically acceptable carrier and/or an adjuvant. For example, the adjuvant can be alum, Freund's complete adjuvant, a biological adjuvant or immunostimulatory oligonucleotides (such as CpG oligonucleotides).

Also provided is a method of immunizing a subject against influenza virus by administering to the subject VLPs containing an optimized influenza HA protein disclosed herein, or administering a composition thereof. In some embodiments of the method, the composition further comprises a pharmaceutically acceptable carrier and/or an adjuvant. For example, the adjuvant can be alum, Freund's complete adjuvant, a biological adjuvant or immunostimulatory oligonucleotides (such as CpG oligonucleotides). In some embodiments, the VLPs (or compositions thereof) are administered intramuscularly.

In some embodiments of the methods of eliciting an immune response or immunizing a subject, the subject is administered about 1 to about 25 μ g of the VLPs containing an optimized HA protein. In particular examples, the subject is administered about 5 to about 20 μ g of the VLPs, or about 10 to about 15 μ g of the VLPs. In one specific non-limiting example, the subject is administered about 15 μ g of the VLPs. However, one of skill in the art is capable of determining a therapeutically effective amount (for example an amount that provides protection against H1N1 influenza virus infection) of VLPs to administer to a subject.

IV. Optimized H1N1 Influenza HA Polypeptides and Polynucleotides

Provided herein are 11 different optimized H1N1 HA polypeptide sequences. H1N1 HA amino acid sequences were downloaded from the NCBI Influenza Virus Resource database. H1N1 HA proteins from 1134 isolates from 1918-2011 were used for generating consensus sequences. Example 1 describes the methods that were used to generate each consensus sequence (see also FIGS. 1-5).

45

50

55

60

65

COBRA METHOD 1 (SEQ ID NO: 1) MKAKLLVLLCAFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLQLGNCSIAGWILGNPECESLFSKESWSYIVETP NSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT ASCSHNGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPS NIGDQRAIYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCOTPO GAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAI AGFI EGGWTGMIDGWYGYHHONEOGSGYAADOKSTONAINGITNKVNSVI EKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYOILAIYSTVASSLVLLVSLGAI SFWMCSNGSLQCRICI

COBRA METHOD 2 (SEQ ID NO: 2) MKAKLLVLLCALTATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLOLGNCSIAGWILGNPECESLFSKKSWSYIAETP NSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT AACSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPS NIGDORALYHTENAYVSVVSSHYNRRFTPEIAKRPKVRDOEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQ GAINSSLPFONVHPVTIGECPKYVRSTKLRMVTGLRNIPSIOSRGLFGAI AGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSOLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAI SFWMCSNGSLOCRICI

COBRA METHOD 3 (SEO ID NO: 3) MKAKLLVLLCAFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLQLGNCSVAGWILGNPECESLISKESWSYIVETP NPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT ASCSHNGKSSFYRNLLWLTEKNGLYPNLSKSYVNNKEKEVLVLWGVHHPS NIGDORALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDOEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCOTPO GAINSSLPFONVHPVTIGECPKYVRSTKLRMVTGLRNIPSIOSRGLFGAI AGET EGGWTGMT DGWYGYHHONEOGSGYAADOKSTONA INGT TNKVNSV T EKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYOILAIYSTVASSLVLLVSLGAI SFWMCSNGSLQCRICI

14

-continued

COBRA METHOD 4 (SEQ ID NO: 4) MKAKLLVLLCALTATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLOLGKCSIAGWILGNPECESLLSKKSWSYIAETP NSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHNVTKGVT ASCSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPS 10 NIGDQRTIYRTENAYVSVVSSNYNRRFTPEIAKRPKVRDQEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDTKCQTPQ GAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAI 15 AGF1EGGWTGMIDGWYGYHHONEOGSGYAADOKSTONAING1TNKVNSVI EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSOLKNNAKEIGNGCFEFYHKCNNECMESVKNGT 20 YDYPKYSEESKLNREKIDGVKLESMGVYOILAIYSTVASSLVLLVSLGAI SEWMCSNGSLOCETCT

COBRA METHOD 5 (SEQ ID NO: 5) 25 MKAKLLVLLCTFTATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLOLGNCSIAGWILGNPECESLLSKKSWSYIVETP ${\tt NSENGTCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT$ 30 AACSHAGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKGKEVLVLWGVHHPS NIGDQQALYQTENAYVSVVSSHYNRKFTPEIAKRPKVRDQEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMHECDTKCQTPQ 35 GAINSSLPFQNIHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAI AGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSOLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAI SFWMCSNGSLOCRICI

COBRA METHOD 6 (SEQ ID NO: 6) MKAKLUVUUCAFTATDADTICIGYHANNSTDTVDTVUEKNVTVTHSVNUU EDSHNGKLCKLKGIAPLQLGKCSIAGWILGNPECESLLSKKSWSYIVETP NSENGTCYPGDFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT AACSHAGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPS NIGDQRALYHTENAYVSVVSSHYNRRFTPEIAKRPKVRDQEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCOTPO GAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAI AGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAI SFWMCSNGSLQCRICI

15

-continued

COBRA METHOD 5 DEGLYCOSYLATED (SEQ ID NO: 7) MKAKLLVLLCTFTATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLQLGNCAIAGWILGNPECESLLSKKSWSYIVETP NSENGTCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHAVTKGVT AACSHAGKSSFYRNLLWLTEKNGSYPNLAKSYVNNKGKEVLVLWGVHHPS NIGDOOALYOTENAYVSVVSSHYNRKETPEIAKRPKVRDOEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNAAMHECDTKCQTPQ GAINSSLPFONIHPVTIGECPKYVRSTKLRMVTGLRNIPSIOSRGLFGAI AGF1 EGGWTGM1DGWYGYHHONEOGSGYAADOKSTONAING1TNKVNSV1 EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSOLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYOILAIYSTVASSLVLLVSLGAI SEWMCSNGSLOCETCT

(SEQ ID NO: 8) MKARLLVLLCALAATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLOLGKCNIAGWILGNPECESLLSNRSWSYIVETP NSENGTCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPKHNTTKGVT AACSHAGKSSFYRNLLWLTEKNGSYPNLSNSYVNNKGKEVLVLWGVHHPS NIDDQQTLYQKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRMNYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMHECDTKCQTPQ GAINSSLPFONIHPVTIGECPKYVRSTKLRMVTGLRNIPSIOSRGLFGAI AGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNNLEKRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSOLRNNAKEIGNGCFEFYHKCDNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAI SFWMCSNGSLOCRICI

1918-1957 COBRA

1977-2005 COBRA (SEO ID NO: 9) MKAKLLVLLCAFTATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDSHNGKLCRLKGIAPLQLGNCSIAGWILGNPECESLFSKKSWSYIAETP NSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVT ASCSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPS NIGDORAIYHTENAYVSVVSSHYNRRFTPEIAKRPKVRDOEGRINYYWTL LEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCOTPO GAINSSLPFONVHPVTIGECPKYVRSTKLRMVTGLRNIPSIOSRGLFGAI AGET EGGWTGMT DGWYGYHHONEOGSGYAADOKSTONA INGT TNKVNSV T EKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGT YDYPKYSEESKLNREKIDGVKLESMGVYOILAIYSTVASSLVLLVSLGAI SFWMCSNGSLQCRICI

-continued

HUMAN SWINE COBRA (SEQ ID NO: 10) MKAILLVLLCTFAATNADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDKHNGKLCKLKGIAPLHLGKCNIAGWLLGNPECELLLTASSWSYIVETS NSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHETNKGVT AACPYAGASSFYRNLIWLVKKGNSYPKLSKSYVNNKGKEVLVLWGIHHPP 10 TSTDQQSLYQNADAYVFVGSSKYNRKFKPEIAARPKVRDQAGRMNYYWTL IEPGDTITFEATGNLVVPRYAFAMNRGSGSGIIISDAPVHDCNTKCQTPK GAINTSLPFQNIHPVTIGECPKYVKSTKLRMATGLRNIPSIQSRGLFGAI AGF1EGGWTGMIDGWYGYHHONEOGSGYAADOKSTONAIDG1TNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVRSOLKNNAKEIGNGCFEFYHKCDDTCMESVKNGT ²⁰ ydypkyseesklnreeidgvklestriyqilaiystvasslvllvslgai SEWMCSNGSLOCEICT

(SEQ ID NO: 11) 25 MKAILLVLLCTFTAANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDRHNGKLCKLGGIAPLHLGKCNIAGWLLGNPECELLLTASSWSYIVETS NSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKASSWPNHETNRGVT 30 AACPYAGANSFYRNLIWLVKKGNSYPKLSKSYVNNKGKEVLVLWGIHHPP TSTDQQSLYQNADAYVFVGSSKYNRKFKPEIAARPKVRGQAGRMNYYWTL LEPGDTITFEATGNLVVPRYAFAMNRGSGSGIIISDAPVHDCNTKCOTPK 35 GAINTSLPFONIHPVTIGECPKYVKSTKLRMATGLRNIPSIOSRGLFGAI AGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAIDGITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDVWTYNAELLVLLENER TLDFHDSNVKNLYEKVRSOLRNNAKEIGNGCFEFYHKCDDTCMESVKNGT YDYPKYSEESKLNREEIDGVKLESTRIYQILAIYSTVASSLVLLVSLGAI SFWMCSNGSLOCRICI

Consensus of SEO ID NOs: 1-11 (SEQ ID NO: 12) MKAXLLVLLCXXXAXXADTXCIGYHANNSTDTVDTVLEKNVTVTHSVNLL EDXHNGKLCXLXGIAPLXLGXCXXAGWXLGNPECEXLXXXXSWSYIXETX NXXNGTCYPGXFXXYEELREQLSSVSSFERFEIFPKXSSWPXHXXXXGVT AXCXXXGXXSFYRNLXWLXXKXXXYPXLXXSYVNNKXKEVLVLWGXHHP XXXXDQXXXYXXXAYVXVXSSXYXRXFXPEIAXRPKVRXQXGRXNYY WTLXEPGDTIXFEAXGNLXXPXYAFAXXRGXGSGIIXSXAXXXXCXXKCO TPXGAINXSLPFONXHPVTIGECPKYVXSTKLRMXTGLRNIPSIOSRGLF GATAGETEGGWTGMTDGWYGYHHONEOGSGYAADOKSTONATXGTTNKVN SVIEKMNTQFTAVGKEFNXLEXRXENLNKKVDDGFLDXWTYNAELLVLLE NERTLDFHDSNVKNLYEKVXSQLXNNAKEIGNGCFEFYHKCXXXCMESVK NGTYDYPKYSEESKLNREXIDGVKLESXXXYQILAIYSTVASSLVLLVSL GAISFWMCSNGSLQCRICI

15

45

50

55

60

65

SWINE COBRA

30

In some embodiments disclosed herein, the HA polypeptides lack the N-terminal methionine residue. Thus, in some examples, provided are HA polypeptides comprising residues 2-566 of any one of SEQ ID NOs: 1-12.

The COBRA amino acid sequences can be reverse trans-5 lated and optimized for expression in mammalian cells, including codon usage and RNA optimization (GeneArt; Regensburg, Germany). The optimized nucleic acid sequences can be inserted into an appropriate expression vector, such as the pTR600 expression vector (U.S. Patent ¹⁰ Application Publication No. 2002/0106798; Ross et al., Nat. Immunol. 1(2):102-103, 2000; Green et al., Vaccine 20:242-248, 2001).

The optimized nucleic acid sequence of the COBRA HA sequence of Method 1 is (SEQ ID NO: 13):

AAGCTTATGAAGGCCAAGCTGCTGGTGCTGCTGCGCGCCTTCACAGCCA CCTACGCCGACACCATCTGCATCGGCTACCACGCCAACAACAGCACCGA CACCGTGGATACCGTGCTGGAAAAGAACGTGACCGTGACCCACAGCGTG AACCTGCTGGAAGATAGCCACAACGGCAAGCTGTGCCGGCTGAAGGGA ATCGCCCCTCTGCAGCTGGGCAACTGCTCTATCGCCGGCTGGATTCTGGG CAACCCCGAGTGCGAGAGCCTGTTCAGCAAAGAGTCCTGGTCCTACATC GTGGAAACCCCCAACAGCGAGAACGGCACCTGTTACCCCGGCTACTTCG CCGACTACGAGGAACTGCGGGAACAGCTGAGCAGCGTGTCCAGCTTCGA GAGATTCGAGATTTTCCCCAAAGAGAGCAGCTGGCCCAACCACCGTG ACCAAAGGCGTGACCGCCTCCTGCTCCCACAATGGCAAGAGCAGCTTCT ACAGAAACCTGCTGTGGCTGACCGAGAAGAACGGCAGCTACCCCAACCT GAGCAAGAGCTACGTGAACAACAAAGAAAAAAGAGGTGCTGGTGCTGTG GGGCGTGCACCACCCTAGCAACATCGGCGACCAGCGGGCCATCTACCAC ACCGAGAATGCCTACGTGTCCCGTGGTGTCCAGCCACTACAGCAGACGGT TCACCCCCGAGATCGCCAAGAGGCCCAAAGTGCGGGACCAGGAAGGCC GGATCAACTACTGGACACTGCTGGAACCCGGCGATACCATCATCTTC GAGGCCAACGGCAACCTGATCGCCCCTTGGTACGCCTTCGCCCTGAGCA GAGGCTTTGGCAGCGGCATCATCACCAGCAACGCCAGCATGGACGAGTG CGACGCCAAGTGCCAGACACCTCAGGGCGCCATCAATAGCAGCCTGCCC TTCCAGAACGTGCACCCCGTGACCATCGGCGAGTGCCCCCAAATACGTGC GGAGCACCAAGCTGCGGATGGTCACCGGCCTGAGAAACATCCCCAGCAT CCAGAGCAGGGGCCTGTTCGGAGCCATTGCCGGCTTTATCGAGGGCGGC TGGACCGGCATGATCGACGGGTGGTACGGCTATCACCACCAGAACGAGC AGGGCAGCGGCTACGCCGCCGATCAGAAGTCTACCCAGAACGCCATCAA CGGCATCACCAACAAAGTGAACAGCGTGATCGAGAAGATGAACACCCA GTTCACCGCCGTGGGCAAAGAGTTCAACAAGCTGGAACGGCGGATGGAA AACCTGAACAAGAAGGTGGACGACGGCTTCCTGGACATCTGGACCTACA ACGCCGAACTGCTGGTGCTGCTGGAAAACGAGCGGACCCTGGACTTCCA CGACAGCAACGTGAAGAACCTGTACGAGAAAGTGAAGTCCCAGCTGAA GAACAACGCCAAAGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAG TGCAACAACGAGTGCATGGAAAGCGTGAAGAATGGCACCTACGACTACC

-continued

CCAAGTACAGCGAGGAAAGCAAGCTGAACCGCGAGAAGATCGACGGCG

TGAAGCTGGAATCCATGGGCGTGTACCAGATCCTGGCCATCTATAGCAC

CGTGGCCAGCAGCCTGGTGCTGCTGGTGTCTCTGGGCGCCATCAGCTTTT

GGATGTGCAGCAACGGCAGCCTGCAGTGCCGGATCTGTATCGGCAGCAT

CGGATCC

V. Influenza

Influenza viruses are segmented negative-strand RNA 15 viruses that belong to the Orthomyxoviridae family. There are three types of Influenza viruses, A, B and C. Influenza A viruses infect a wide variety of birds and mammals, including humans, horses, marine mammals, pigs, ferrets, and chickens. In animals, most influenza A viruses cause mild 20 localized infections of the respiratory and intestinal tract. However, highly pathogenic influenza A strains, such as H5N1, cause systemic infections in poultry in which mortality may reach 100%. Animals infected with influenza A often act as a reservoir for the influenza viruses and certain subtypes have been shown to cross the species barrier to humans.

Influenza A viruses can be classified into subtypes based on allelic variations in antigenic regions of two genes that encode surface glycoproteins, namely, hemagglutinin (HA) and neuraminidase (NA) which are required for viral attachment and cellular release. Currently, sixteen subtypes of HA (H1-H16) and nine NA (N1-N9) antigenic variants are known for influenza A virus. Previously, only three subtypes were known to circulate in humans (H1N1, H1N2, and

35 H3N2). However, in recent years, the pathogenic H5N1 subtype of avian influenza A has been reported to cross the species barrier and infect humans as documented in Hong Kong in 1997 and 2003, leading to the death of several patients.

In animals, most influenza A viruses cause mild localized 40 infections of the respiratory and intestinal tract. However, highly pathogenic influenza A strains, such as H5N1, cause systemic infections in poultry in which mortality may reach 100%. In 2009, H1N1 influenza was the most common 45 cause of human influenza. A new strain of swine-origin H1N1 emerged in 2009 and was declared pandemic by the World Health Organization. This strain was referred to as "swine flu." H1N1 influenza A viruses were also responsible for the Spanish flu pandemic in 1918, the Fort Dix outbreak 50 in 1976, and the Russian flu epidemic in 1977-1978.

The influenza A virus genome encodes nine structural proteins and one nonstructural (NS1) protein with regulatory functions. The influenza virus segmented genome contains eight negative-sense RNA (nsRNA) gene segments (PB2, 55 PB1, PA, NP, M, NS, HA and NA) that encode at least ten polypeptides, including RNA-directed RNA polymerase proteins (PB2, PB1 and PA), nucleoprotein (NP), neuraminidase (NA), hemagglutinin (subunits HA1 and HA2), the matrix proteins (M1 and M2) and the non-structural proteins

(NS1 and NS2) (Krug et al., In "The Influenza Viruses," R. 60 M. Krug, ed., Plenum Press, N.Y., 1989, pp. 89 152).

Influenza virus' ability to cause widespread disease is due to its ability to evade the immune system by undergoing antigenic change, which is believed to occur when a host is 65 infected simultaneously with both an animal influenza virus and a human influenza virus. During mutation and reassortment in the host, the virus may incorporate an HA and/or NA

surface protein gene from another virus into its genome, thereby producing a new influenza subtype and evading the immune system.

HA is a viral surface glycoprotein generally comprising approximately 560 amino acids and representing 25% of the 5 total virus protein. It is responsible for adhesion of the viral particle to, and its penetration into, a host cell in the early stages of infection. Cleavage of the virus HA0 precursor into the HA1 and HA2 sub-fragments is a necessary step in order for the virus to infect a cell. Thus, cleavage is required in 10 order to convert new virus particles in a host cell into virions capable of infecting new cells. Cleavage is known to occur during transport of the integral HA0 membrane protein from the endoplasmic reticulum of the infected cell to the plasma membrane. In the course of transport, hemagglutinin under-15 goes a series of co- and post-translational modifications including proteolytic cleavage of the precursor HA into the amino-terminal fragment HA1 and the carboxy terminal HA2. One of the primary difficulties in growing influenza strains in primary tissue culture or established cell lines 20 arises from the requirement for proteolytic cleavage activation of the influenza hemagglutinin in the host cell.

Although it is known that an uncleaved HA can mediate attachment of the virus to its neuraminic acid-containing receptors on a cell surface, it is not capable of the next step 25 in the infectious cycle, which is fusion. It has been reported that exposure of the hydrophobic amino terminus of HA2 by cleavage is required so that it can be inserted into the target cell, thereby forming a bridge between virus and target cell membrane. This process is followed by fusion of the two 30 membranes and entry of the virus into the target cell.

Proteolytic activation of HA involves cleavage at an arginine residue by a trypsin-like endoprotease, which is often an intracellular enzyme that is calcium dependent and has a neutral pH optimum. Since the activating proteases are 35 cellular enzymes, the infected cell type determines whether the HA is cleaved. The HA of the mammalian influenza viruses and the nonpathogenic avian influenza viruses are susceptible to proteolytic cleavage only in a restricted number of cell types. On the other hand, HA of pathogenic avian 40 viruses among the H5 and H7 subtypes are cleaved by proteases present in a broad range of different host cells. Thus, there are differences in host range resulting from differences in hemagglutinin cleavability which are correlated with the pathogenic properties of the virus. 45

Neuraminidase (NA) is a second membrane glycoprotein of the influenza viruses. The presence of viral NA has been shown to be important for generating a multi-faceted protective immune response against an infecting virus. For most influenza A viruses, NA is 413 amino acid in length, and is 50 encoded by a gene of 1413 nucleotides. Nine different NA subtypes have been identified in influenza viruses (N1, N2, N3, N4, N5, N6, N7, N8 and N9), all of which have been found among wild birds. NA is involved in the destruction of the cellular receptor for the viral HA by cleaving terminal 55 neuraminic acid (also called sialic acid) residues from carbohydrate moieties on the surfaces of infected cells. NA also cleaves sialic acid residues from viral proteins, preventing aggregation of viruses. Using this mechanism, it is hypothesized that NA facilitates release of viral progeny by 60 preventing newly formed viral particles from accumulating along the cell membrane, as well as by promoting transportation of the virus through the mucus present on the mucosal surface. NA is an important antigenic determinant that is subject to antigenic variation.

In addition to the surface proteins HA and NA, influenza virus comprises six additional internal genes, which give

65

rise to eight different proteins, including polymerase genes PB1, PB2 and PA, matrix proteins M1 and M2, nucleoprotein (NP), and non-structural proteins NS1 and NS2 (Horimoto et al., Clin Microbiol Rev. 14(1):129-149, 2001).

In order to be packaged into progeny virions, viral RNA is transported from the nucleus as a ribonucleoprotein (RNP) complex composed of the three influenza virus polymerase proteins, the nucleoprotein (NP), and the viral RNA, in association with the influenza virus matrix 1 (M1) protein and nuclear export protein (Marsh et al., J Virol, 82:2295-2304, 2008). The M1 protein that lies within the envelope is thought to function in assembly and budding. A limited number of M2 proteins are integrated into the virions (Zebedee, J. Virol. 62:2762-2772, 1988). They form tetramers having H+ ion channel activity, and when activated by the low pH in endosomes, acidify the inside of the virion, facilitating its uncoating (Pinto et al., Cell 69:517-528, 1992). Amantadine is an anti-influenza drug that prevents viral infection by interfering with M2 ion channel activity, thus inhibiting virus uncoating.

NS1, a nonstructural protein, has multiple functions, including regulation of splicing and nuclear export of cellular mRNAs as well as stimulation of translation. The major function of NS1 seems to be to counteract the interferon activity of the host, since an NS1 knockout virus was viable although it grew less efficiently than the parent virus in interferon-nondefective cells (Garcia-Sastre, Virology 252: 324-330, 1998).

NS2 has been detected in virus particles (Richardson et al., Arch. Virol. 116:69-80, 1991; Yasuda et al., Virology 196:249-255, 1993). The average number of NS2 proteins in a virus particle was estimated to be 130-200 molecules. An in vitro binding assay shows direct protein-protein contact between M1 and NS2. NS2-M1 complexes have also been detected by immunoprecipitation in virus-infected cell lysates. The NS2 protein is thought to play a role in the export of RNP from the nucleus through interaction with M1 protein (Ward et al., Arch. Virol. 140:2067-2073, 1995).

VI. Influenza VLPs and Administration Thereof

Influenza VLPs comprising an optimized HA (such as the HA having the amino acid sequence set forth as any one of SEQ ID NOs: 1-11) are provided herein. The influenza VLPs are generally made up of the HA, NA and M1 proteins. The production of influenza VLPs has been described in the art and is within the abilities of one of ordinary skill in the art. For example, influenza VLPs can be produced by transfection of host cells with plasmids encoding the HA, NA and M1 proteins. After incubation of the transfected cells for an appropriate time to allow for protein expression (such as for approximately 72 hours), VLPs can be isolated from cell culture supernatants. Example 2 below provides an exemplary protocol for purifying influenza VLPs from cell supernatants. In this example, VLPs are isolated by low speed centrifugation (to remove cell debris), vacuum filtration and ultracentrifugation through 20% glycerol.

The influenza VLPs disclosed herein can be used as influenza vaccines to elicit a protective immune response against H1N1 influenza viruses.

Influenza VLPs, or compositions thereof, can be administered to a subject by any of the routes normally used for introducing recombinant virus into a subject. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, parenteral, intravenous, subcutaneous, vaginal, rectal, intranasal, inhalation or oral. Parenteral administration, such as subcutaneous, intravenous or intramuscular administration, is generally achieved by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Injection solutions and suspensions 5 can be prepared from sterile powders, granules, and tablets of the kind previously described. Administration can be systemic or local.

Influenza VLPs, or compositions thereof, are administered in any suitable manner, such as with pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compo- 15 sitions of the present disclosure.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glvcol, polyethylene glvcol, vegetable oils such as olive oil, 20 and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ring- 25 er's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert 30 gases and the like.

Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base-addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, 35 thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium 40 lyseryl-serine can be used to prime tumor specific CTL when hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

Administration can be accomplished by single or multiple doses. The dose administered to a subject in the context of 45 the present disclosure should be sufficient to induce a beneficial therapeutic response in a subject over time, or to inhibit or prevent H1N1 influenza virus infection. The dose required will vary from subject to subject depending on the species, age, weight and general condition of the subject, the 50 severity of the infection being treated, the particular composition being used and its mode of administration. An appropriate dose can be determined by one of ordinary skill in the art using only routine experimentation.

Provided herein are pharmaceutical compositions which 55 include a therapeutically effective amount of the influenza VLPs alone or in combination with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. 60 The carrier and composition can be sterile, and the formulation suits the mode of administration. The composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, 65 sustained release formulation, or powder. The composition can be formulated as a suppository, with traditional binders

and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. Any of the common pharmaceutical carriers, such as sterile saline solution or sesame oil, can be used. The medium can also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, buffers, preservatives and the like. Other media that can be used with the compositions and methods provided herein are normal saline and sesame oil.

The influenza VLPs described herein can be administered alone or in combination with other therapeutic agents to enhance antigenicity. For example, the influenza VLPs can be administered with an adjuvant, such as Freund incomplete adjuvant or Freund's complete adjuvant.

Optionally, one or more cytokines, such as IL-2, IL-6, IL-12, RANTES, GM-CSF, TNF- α , or IFN- γ , one or more growth factors, such as GM-CSF or G-CSF; one or more molecules such as OX-40L or 41 BBL, or combinations of these molecules, can be used as biological adjuvants (see, for example, Salgaller et al., 1998, J. Surg. Oncol. 68(2): 122-38; Lotze et al., 2000, Cancer J. Sci. Am. 6(Suppl 1):S61-6; Cao et al., 1998, Stem Cells 16(Suppl 1):251-60; Kuiper et al., 2000, Adv. Exp. Med. Biol. 465:381-90). These molecules can be administered systemically (or locally) to the host

A number of means for inducing cellular responses, both in vitro and in vivo, are known. Lipids have been identified as agents capable of assisting in priming CTL in vivo against various antigens. For example, as described in U.S. Pat. No. 5,662,907, palmitic acid residues can be attached to the alpha and epsilon amino groups of a lysine residue and then linked (for example, via one or more linking residues, such as glycine, glycine-glycine, serine, serine-serine, or the like) to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated in a liposome, or emulsified in an adjuvant. As another example, E. coli lipoproteins, such as tripalmitoyl-S-glycerylcysteincovalently attached to an appropriate peptide (see, Deres et al., Nature 342:561, 1989). Further, as the induction of neutralizing antibodies can also be primed with the same molecule conjugated to a peptide which displays an appropriate epitope, two compositions can be combined to elicit both humoral and cell-mediated responses where that is deemed desirable.

Although administration of VLPs containing an optimized HA protein is exemplified herein, one of skill in the art would understand that it is also possible to administer the optimized influenza HA protein itself (in the absence of a viral particle) or as a fusion protein to elicit an immune response in a subject.

The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.

EXAMPLES

Example 1

Generation of COBRA Sequences for H1N1 Influenza

Influenza A H1N1 HA amino acid sequences were downloaded from the NCBI Influenza Virus Resource database. H1N1 HA proteins from 1134 isolates from 1918-2011 were used for generating consensus sequences. Eleven different consensus sequences (SEQ ID NOs: 1-11) were generated using the following methods:

1. COBRA Method 1 (1918-2005)

Sequences (456) were organized by date of isolation and eight primary consensus sequences were generated using isolates from 1918-1934 (8), 1935-1947 (13), 1948-1957 (12), 1977-1983 (68), 1984-1986 (9), 1987-1991 (12), 1992-1999 (59) and 2000-2005 (263). Four secondary consensus sequences were generated by grouping the primary consensus sequences by date, as shown in FIG. **1**. The final consensus sequence (the third layer consensus; SEQ ID NO: 1) was generated by alignment of the four secondary consensus sequences.

2. COBRA Method 2 (1918-2005)

As with method 1, sequences (456) were organized by date of isolation to generate eight primary consensus sequences. The final consensus sequence (SEQ ID NO: 2) 20 248, 2001). was generated by aligning the eight primary consensus sequences, as illustrated in FIG. **2**.

3. COBRA Method 3 (1918-2005)

The consensus sequence (SEQ ID NO: 3) was generated by alignment of 456 H1N1 virus isolates from 1918-2005. ²⁵ 4. COBRA Method 4 (1918-2005)

Sequences (456) were organized by date of isolation and ten primary consensus sequences were generated using isolates from 1918-1933 (6), 1934-1946 (15), 1947-1956 (12), 1957-1977 (8), 1978-1980 (17), 1981-1985 (49), 1986-1990 (14), 1991-1995 (27), 1996-1998 (27) and 1999-2005 (281), as shown in FIG. **3**. The final consensus sequence (SEQ ID NO: 4) was generated by alignment of the ten primary consensus sequences.

5. COBRA Method 5 (1918-2011)

Sequences (1134) were organized by date of isolation and 12 primary consensus sequences were generated using isolates from 1918 (1), 1976 (4), 2009-2011 (123), 1933-1934 (8), 1935-1947 (13), 1948-1957 (12), 1977-1983 (68), 1984-1986 (9), 1987-1991 (12), 1992-1999 (27), 2000-2005 (59) and 2006-2008 (798). Four secondary consensus sequences were generated by grouping the primary consensus sequences according to "swine" sequences or by date, as shown in FIG. **4**. The final consensus sequence (the third ⁴⁵ layer consensus; SEQ ID NO: 5) was generated by alignment of the four secondary consensus sequences. 6. COBRA Method 6

Sequences (1134) were organized by date of isolation and 13 primary consensus sequences were generated using isolates from 1918 (1), 1933-1934 (8), 1935-1947 (13), 1948-1957 (12), 1976 (4), 1977-1983 (68), 1984-1986 (9), 1987-1991 (12), 1992-1999 (27), 2000-2005 (59), 2006 (76), 2007-2008 (722) and 2009-2011 (123), as shown in FIG. **5**. The final consensus sequence (SEQ ID NO: 6) was generated by alignment of the 13 primary consensus sequences. 7. COBRA Method 5 Deglycosylated

This sequence (SEQ ID NO: 7) was generated by altering the Method 5 consensus sequence (SEQ ID NO: 5) to $_{60}$ remove predicted glycosylation sites.

8. 1918-1957 COBRA

This sequence (SEQ ID NO: 8) was generated by alignment of H1N1 isolates from 1918-1957. 9. 1977-2005 COBRA

This sequence (SEQ ID NO: 9) was generated by alignment of H1N1 isolates from 1977-2005.

10. Human Swine COBRA

This sequence (SEQ ID NO: 10) was generated by alignment of H1N1 human swine influenza isolates. This sequence was aligned using consensus sequences from 1918, 1976 and 2009-2011.

11. Swine COBRA

This sequence (SEQ ID NO: 11) was generated by alignment of H1N1 swine influenza isolates. This sequence was aligned using swine sequences from 1930-2010.

The COBRA amino acid sequence generated according to Method 1 was reverse translated and optimized for expression in mammalian cells, including codon usage and RNA optimization (GeneArt; Regensburg, Germany). The optimized nucleic acid sequence is set forth herein as SEQ ID NO: 13. The remaining COBRA sequences will also be reverse translated and optimized for expression in mammalian cells. The optimized nucleic acid sequences will be inserted into the pTR600 expression vector (U.S. Patent Application Publication No. 2002/0106798; Ross et al., *Nat. Immunol.* 1(2):102-103, 2000; Green et al., *Vaccine* 20:242-248, 2001).

Example 2

Preparation of and Immunization with Influenza VLPs

The following methods can be used to produce and characterize influenza VLPs comprising an optimized HA. Exemplary methods for immunization of mice, ferrets and macaques are also described below (see also, Giles and Ross, Vaccine 29(16):3043-3054, 2011).

Vaccine Preparation

293T cells are transiently transfected with plasmids expressing M1, NA and an optimized HA, and incubated for
72 hours at 37° C. The M1, NA and HA coding sequences can be codon-optimized for expression in mammalian cells. Supernatants are collected and cell debris is removed by low speed centrifugation followed by vacuum filtration through a 0.22 µm sterile filter. VLPs are purified via ultracentrifu-40 gation (100,000×g through 20% glycerol, weight per volume) for 4 hours at 4° C. The pellets are subsequently resuspended in PBS pH 7.2 and stored in single use aliquots at -80° C. until use. Total protein concentration is determined by Micro BCATM Protein Assay Reagent Kit (Pierce 45 Biotechnology, Rockford, Ill., USA).

Dose Determination

HA specific content can be determined by western blot and densitometry. Purified recombinant COBRA HA and purified VLPs are prepared in standard total protein amounts and are electrophoresed on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The blot is probed with mouse polyclonal antisera from influenza infected mice and the HA-antibody complexes are detected using a goat antimouse IgG conjugated to horseradish peroxidase (HRP) (Southern Biotech; Birmingham, Ala., USA). HRP is detected by chemiluminescent substrate (Pierce Biotechnology; Rockford Ill., USA) and exposed to X-ray film (ThermoFisher; Pittsburgh, Pa., USA). Density of bands is determined using ImageJ software (NIH). Density of recombinant HA bands is used to calculate a standard curve and the density of the purified VLPs is interpolated using the results from the recombinant HA. Mouse Studies

BALB/c mice (*Mus musculis*, females, 6-8 weeks old) can 65 be purchased from Harlan Sprague Dawley (Indianapolis, Ind., USA). Mice are housed in microisolator units and allowed free access to food and water and are cared for

Primate Immunizations

under USDA guidelines for laboratory animals. Mice are vaccinated with one of three doses of purified COBRA HA VLPs (1.5 µg, 0.3 µg or 0.06 µg), based upon HA content from a densitometry assay, via intramuscular injection at week 0 and then boosted with the same dose at week 3. Vaccines at each dose are formulated with alum adjuvant (Imject Alum, Pierce Biotechnology; Rockford, Ill., USA), CpG oligonucleotides, or vehicle alone. Fourteen to twentyone days after each vaccination, blood is collected from anesthetized mice via the retro-orbital plexus and transferred to a microfuge tube. Tubes are centrifuged and sera is removed and frozen at -80±5° C. Hemagglutination inhibition (HAI) serum antibody titer for each vaccine group is determined at week 5 using representative reassortant 15 viruses or COBRA HA VLPs.

Three weeks after final vaccination, mice are challenged intranasally with a highly pathogenic H1N1 virus in a volume of 50 µl. After infection, mice are monitored daily for weight loss, disease signs and death for 14 days after 20 infection. Individual body weights, sickness scores (Toapanta and Ross, *Respiratory Research* 10(1):112, 2009) and death are recorded for each group on each day after inoculation.

Ferret Studies

Fitch ferrets (Mustela putorius faro, female, 6-12-months of age), influenza naïve and de-scented, can be purchased from Marshall Farms (Sayre, Pa., USA). Ferrets are pair 30 housed in stainless steel cages (Shor-line, Kansas City, Kans., USA) containing Sani-chips Laboratory Animal Bedding (P. J. Murphy Forest Products, Montville, N.J., USA). Ferrets are provided with Teklad Global Ferret Diet (Harlan Teklad, Madison, Wis., USA) and fresh water ad libitum. 35 The COBRA HAVLPs are diluted in PBS, pH 7.2 to achieve final concentration. Ferrets are vaccinated with one of two doses of purified COBRA VLPs (15 µg, 3 µg), based upon HA content as determined by densitometry assay, via intramuscular injection in the quadriceps muscle in a volume of $_{40}$ in Example 2. Mice were inoculated with the VLPs and 0.25 ml at week 0 and then boosted with the same dose at week 3. Vaccines are stored at -80° C. prior to use and formulated with alum adjuvant (Imject Alum; Pierce Biotechnology, Rockford, Ill., USA) immediately prior to use. Animals are monitored for adverse events including weight 45 loss, temperature, decrease in activity, nasal discharge, sneezing and diarrhea weekly during the vaccination regimen. Prior to vaccination, animals are confirmed by HAI assay to be seronegative for circulating influenza A and influenza B viruses. Fourteen to twenty-one days after each vaccination, blood is collected from anesthetized ferrets via the anterior vena cava and transferred to a microfuge tube. Tubes are centrifuged and sera is removed and frozen at -80±5° C. HAI serum antibody titer for each vaccine group is determined at week 5 using representative reassortant viruses or COBRA HA VLPs.

Three weeks after final vaccination, ferrets are challenged intranasally with a highly pathogenic H1N1 virus in a volume of 1 ml. After infection, ferrets are monitored daily 60 for weight loss, disease signs and death for 14 days after infection. Individual body weights, sickness scores, and death are recorded for each group on each day after inoculation. Nasal washes are performed by instilling 3 ml of PBS into the nares of anesthetized ferrets each day for 7 days 65 after inoculation. Washes are collected and stored at -80° C. until use.

26

Cynomolgus macaques (Macaca fascicularis, male, 3-5 years old) can be purchased from Harlan Sprague Dawley (Indianapolis, Ind., USA). Macaques are vaccinated with purified COBRA HA VLPs (15 µg), based upon HA content from a densitometry assay, via intramuscular injection at week 0 and then boosted with the same dose at weeks 3 and 6. Vaccines are formulated with alum adjuvant (Imject Alum, Pierce Biotechnology; Rockford, Ill., USA) immediately prior to use. Twenty-one days after each vaccination, blood is collected from anesthetized macaques via the femoral vein and transferred to a serum separator tube. Tubes are allowed to activate clotting followed by centrifugation and sera is removed and frozen at -80±5° C. End point IgG titers and HAI serum antibody titer for each vaccine group is determined at week 5 using representative reassortant viruses or COBRA HA VLPs.

Three weeks after final vaccination, macaques are challenged by intranasal, intratracheal, and orbital inoculation with a highly pathogenic H1N1 virus in a volume of 1 ml. After infection, macaques are monitored daily for weight loss, disease signs and death for 5 days after infection. Individual body weights, sickness scores and death are recorded for each group on each day after inoculation.

Example 3

Analysis of COBRA H1N1 Method 1 HA

This example describes the finding that inoculation of mice with COBRA H1N1 influenza VLPs induces significant HAI serum antibody titers, and further shows that translation of COBRA H1N1 HA in vitro results in expression of the protein at the expected molecular weight.

HAI Serum Antibody Titers

To evaluate whether influenza virus containing COBRA Method 1 H1N1 HA is capable of eliciting an antibody response in infected animals, VLPs comprising the COBRA Method 1 HA (SEQ ID NO: 1) were generated as described serum was collected at weeks 3, 5, 8 and 12 post-infection for determination of HAI serum antibody titers. Antisera were tested against the seasonal H1N1 influenza virus, A/New Calcdonia/20/1999. As shown in FIG. 6, HAI titers were detected starting at 5 weeks post-infection and increased at weeks 8 and 12.

Expression of COBRA HA In Vitro

As described in Example 2, the COBRA HA Method 1 amino acid sequence was reverse translated and optimized for expression in mammalian cells. The optimized nucleic acid sequence (SEQ ID NO: 13) encoding COBRA HA was inserted into the pTR600 expression vector. To assess whether COBRA H1N1 HA is properly expressed in vitro, cells were transfected with the pTR600 expression vector encoding COBRA H1N1 HA. Cell culture lysates were analyzed by SDS-PAGE, followed by Western blot for detection of influenza HA. As shown in FIG. 7, COBRA HA migrated to its expected molecular weight, confirming expression of the synthetic protein in vitro.

In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1 <211> LENGTH: 566 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic polypeptide <400> SEQUENCE: 1 Met Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Phe Thr Ala Thr Tyr 1 5 10 15 Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys Gly Ile Ala Pro Leu Gln Leu Gly Asn Cys Ser Ile Ala Gly Trp Ile Leu Gly 65 70 75 80 Asn Pro Glu Cys Glu Ser Leu Phe Ser Lys Glu Ser Trp Ser Tyr Ile Val Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Tyr Phe Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr Val Thr Lys Gly Val Thr Ala Ser Cys Ser His Asn Gly Lys Ser Ser Phe Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys Asn Gly Ser Tyr Pro Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu Val Leu Val Leu Trp Gly Val His His Pro Ser Asn Ile Gly Asp Gln Arg Ala Ile Tyr His Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser His Tyr Ser 210 215 220 Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val Arg Asp Gln Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser Asn Ala Ser Met Asp Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly Ala Ile Asn Ser Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile Gly Glu Cys Pro Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Val Thr Gly Leu Arg Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly Tyr

-continued

| | | | | | | | | | | | _ | COII | | ueu | |
|--------------------------------------|--------------------------------------|------------|------------------------------------|--------------------|------------|----------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| | | 355 | | | | | 360 | | | | | 365 | | | |
| | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | Lys | Glu | Phe | Asn 415 | Lys |
| Leu | Glu | Arg | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Lys | Ser | Gln | Leu 470 | Lys | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| Cys | Phe | Glu | Phe | Tyr 485 | His | Lys | Cys | Asn | Asn 490 | Glu | Cys | Met | Glu | Ser 495 | Val |
| Lys . | Asn | Gly | Thr 500 | Tyr | Asp | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn . | Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| | Ile 530 | Leu | Ala | Ile | Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val 545 | Ser | Leu | Gly | Ala | Ile 550 | Ser | Phe | Trp | Met | Сув 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln | Суз | Arg | Ile | Cys 565 | Ile | | | | | | | | | | |
| <211 <212 <213 <220 <223 | > LE > T\ > OF > FE > OT | ATUF | I: 50 PRT SM: RE: INF(| 56 Art: DRMA | | ial : : Syn | - | | poly | pepti | ide | | | | |
| Met 1 | Lys | Ala | Lys | Leu 5 | Leu | Val | Leu | Leu | Cys 10 | Ala | Leu | Thr | Ala | Thr 15 | Asp |
| Ala . | Asp | Thr | Ile 20 | Суз | Ile | Gly | Tyr | His 25 | Ala | Asn | Asn | Ser | Thr 30 | Asp | Thr |
| Val | Asp | Thr 35 | Val | Leu | Glu | Гла | Asn 40 | Val | Thr | Val | Thr | His 45 | Ser | Val | Asn |
| | Leu 50 | Glu | Asp | Ser | His | Asn 55 | Gly | Гла | Leu | Суз | Arg 60 | Leu | ГЛа | Gly | Ile |
| Ala 65 | Pro | Leu | Gln | Leu | Gly 70 | Asn | Сув | Ser | Ile | Ala 75 | Gly | Trp | Ile | Leu | Gly 80 |
| Asn | Pro | Glu | Суз | Glu 85 | Ser | Leu | Phe | Ser | Lys 90 | Lys | Ser | Trp | Ser | Tyr 95 | Ile |
| Ala | Glu | Thr | Pro 100 | Asn | Ser | Glu | Asn | Gly 105 | Thr | Суз | Tyr | Pro | Gly 110 | Tyr | Phe |
| Ala . | Asp | Tyr 115 | Glu | Glu | Leu | Arg | Glu 120 | Gln | Leu | Ser | Ser | Val 125 | Ser | Ser | Phe |
| | Arg 130 | Phe | Glu | Ile | Phe | Pro 135 | Lys | Glu | Ser | Ser | Trp 140 | Pro | Asn | His | Thr |
| Val | Thr | Lys | Gly | Val | Thr | Ala | Ala | Суз | Ser | His | Lys | Gly | Lys | Ser | Ser |

| | | | | | | | | | | | | con | tin | uea | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| 145 | _ | _ | _ | _ | 150 | | | _ | _ | 155 | _ | _ | _ | _ | 160 |
| Phe | Tyr | Arg | Asn | Leu 165 | Leu | Trp | Leu | Thr | Glu 170 | Lys | Asn | Gly | Ser | Tyr 175 | Pro |
| Asn | Leu | Ser | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Glu | ГЛЗ | Glu | Val 190 | Leu | Val |
| Leu | Trp | Gly 195 | Val | His | His | Pro | Ser 200 | Asn | Ile | Gly | Asp | Gln 205 | Arg | Ala | Ile |
| Tyr | His 210 | Thr | Glu | Asn | Ala | Tyr 215 | Val | Ser | Val | Val | Ser 220 | Ser | His | Tyr | Asn |
| Arg 225 | Arg | Phe | Thr | Pro | Glu 230 | Ile | Ala | Lys | Arg | Pro 235 | ГЛа | Val | Arg | Asp | Gln 240 |
| Glu | Gly | Arg | Ile | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Ile | Phe | Glu 260 | Ala | Asn | Gly | Asn | Leu 265 | Ile | Ala | Pro | Trp | Tyr 270 | Ala | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ser |
| Met | Asp 290 | Glu | Cys | Asp | Ala | Lys 295 | Cys | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Val | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Cys 320 |
| Pro | Lys | Tyr | Val | Arg 325 | Ser | Thr | Гла | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | Lys | Glu | Phe | Asn 415 | Lys |
| Leu | Glu | Lys | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Lys | Ser | Gln | Leu 470 | Lys | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| Суз | Phe | Glu | Phe | Tyr 485 | His | Lys | Сүз | Asn | Asn 490 | Glu | СЛа | Met | Glu | Ser 495 | Val |
| Lys | Asn | Gly | Thr 500 | Tyr | Asp | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn | Arg | Glu 515 | Lys | Ile | Aap | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln | Ile 530 | | Ala | Ile | Tyr | Ser 535 | | Val | Ala | Ser | Ser 540 | | Val | Leu | Leu |
| | | Leu | Gly | Ala | | Ser | Phe | Trp | Met | | | Asn | Gly | Ser | |
| 545 Gln | Cys | Arg | Ile | - | 550 Ile | | | | | 555 | | | | | 560 |
| | | | | 565 | | | | | | | | | | | |

<210> SEQ ID NO 3 <211> LENGTH: 566 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic polypeptide <400> SEQUENCE: 3 Met Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Phe Thr Ala Thr Tyr Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys Gly Ile Ala Pro Leu Gln Leu Gly Asn Cys Ser Val Ala Gly Trp Ile Leu Gly Asn Pro Glu Cys Glu Ser Leu Ile Ser Lys Glu Ser Trp Ser Tyr Ile Val Glu Thr Pro Asn Pro Glu Asn Gly Thr Cys Tyr Pro Gly Tyr Phe Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr Val Thr Lys Gly Val Thr Ala Ser Cys Ser His Asn Gly Lys Ser Ser Phe Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys Asn Gly Leu Tyr Pro Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu Val Leu Val Leu Trp Gly Val His His Pro Ser Asn Ile Gly Asp Gln Arg Ala Leu 2.05 Tyr His Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser His Tyr Ser Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val Arg Asp Gln Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser Asn Ala Ser Met Asp Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly Ala Ile Asn Ser Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile Gly Glu Cys Pro Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Val Thr Gly Leu Arg Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly Tyr

-continued

| 370 | Glu Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
|--|---|--|---|--|---|--|--|---|--|---|---|
| Thr Gln Asn Ala 385 | Ile Asn 390 | | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu Lys Met Asn | Thr Gln 405 | Phe | Thr | Ala | Val 410 | Gly | Lys | Glu | Phe | Asn 415 | Гла |
| Leu Glu Arg Arg 420 | | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu Asp Ile Trp 435 | Thr Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu Arg Thr Leu 450 | Asp Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys Val Lys Ser 465 | Gln Leu 470 | | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| Cys Phe Glu Phe | Tyr His 485 | Lys | Сүз | Asn | Asn 490 | Glu | Cys | Met | Glu | Ser 495 | Val |
| Lys Asn Gly Thr 500 | | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | ràa | Leu |
| Asn Arg Glu Lys 515 | Ile Asp | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln Ile Leu Ala 530 | Ile Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val Ser Leu Gly 545 | Ala Ile 550 | | Phe | Trp | Met | Cys 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln Cys Arg Ile | Cys Ile 565 | | | | | | | | | | |
| | | | | | | | | | | | |
| <pre><210> SEQ ID NC <211> LENGTH: 5 <212> TYPE: PRI <213> ORGANISM: <220> FEATURE: <223> OTHER INF</pre> | 66 Artific | | - | | oolyr | pept: | lde | | | | |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE:</pre> | 66 Artific ORMATION | | - | | oolyr | pept: | ide | | | | |
| <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF | 66 Artific ORMATION 4 | : Syı | nthet | ic p | | | | Thr | Ala | Thr 15 | Asp |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys</pre> | 66 Artific ORMATION 4 Leu Leu 5 | : Syn Val | nthet Leu | tic p Leu | Суз 10 | Ala | Leu | | | 15 | |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile | : Syn Val Gly | Leu Tyr | Leu His 25 | Cys 10 Ala | Ala Asn | Leu Asn | Ser | Thr 30 | 15 Asp | Thr |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu | : Syr Val Gly Lys | Leu Tyr Asn 40 | Leu His 25 Val | Cys 10 Ala Thr | Ala Asn Val | Leu Asn Thr | Ser His 45 | Thr 30 Ser | 15 Asp Val | Thr Asn |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <212> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val 35 Leu Leu Glu Asp</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu Ser His | : Syn Val Gly Lys Asn 55 | Leu Tyr Asn 40 Gly | Leu His 25 Val Lys | Cys 10 Ala Thr Leu | Ala Asn Val Cys | Leu Asn Thr Arg 60 | Ser His 45 Leu | Thr 30 Ser Lys | 15 Asp Val Gly | Thr Asn Ile |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val 35 Leu Leu Glu Asp 50 Ala Pro Leu Gln</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu Ser His Leu Gly 70 | : Syn Val Gly Lys Asn 55 Lys | Leu Tyr Asn 40 Gly Cys | Leu His 25 Val Lys Ser | Cys 10 Ala Thr Leu Ile | Ala Asn Val Cys Ala 75 | Leu Asn Thr Arg 60 Gly | Ser His 45 Leu Trp | Thr 30 Ser Lys Ile | 15 Asp Val Gly Leu | Thr Asn Ile Gly 80 |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <212> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val 35 Leu Leu Glu Asp 50 Ala Pro Leu Gln 65</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu Ser His Leu Gly 70 Glu Ser 85 Asn Ser | : Syn Val Gly Lys Asn 55 Lys Leu | Leu Tyr Asn 40 Gly Cys Leu | Leu His 25 Val Lys Ser Ser | Cys 10 Ala Thr Leu Ile Lys 90 | Ala Asn Val Cys Ala 75 Lys | Leu Asn Thr Arg 60 Gly Ser | Ser His 45 Leu Trp Trp | Thr 30 Ser Lys Ile Ser | 15 Asp Val Gly Leu Tyr 95 | Thr Asn Ile Gly 80 Ile |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: <220> FEATURE: <223> OTHER INF <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val 35 Leu Leu Glu Asp 50 Ala Pro Leu Gln 65 Asn Pro Glu Cys Ala Glu Thr Pro</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu Ser His Leu Gly 70 Glu Ser 85 Asn Ser | : Syı Val Gly Lys Lys Lys Leu Glu | Leu Tyr Asn 40 Gly Cys Leu Asn | Leu His 25 Val Lys Ser Ser Gly 105 | Cys 10 Ala Thr Leu Ile Lys 90 Thr | Ala Asn Val Cys Ala 75 Lys Cys | Leu Asn Thr Arg 60 Gly Ser Tyr | Ser His 45 Leu Trp Trp Pro | Thr 30 Ser Lys Ile Ser Gly 110 | 15 Asp Val Gly Leu Tyr 95 Tyr | Thr Asn Ile Gly 80 Ile Phe |
| <pre><211> LENGTH: 5 <212> TYPE: PRT <212> TYPE: PRT <210> FEATURE: <220> FEATURE: <400> SEQUENCE: Met Lys Ala Lys 1 Ala Asp Thr Ile 20 Val Asp Thr Val 35 Leu Leu Glu Asp 50 Ala Pro Leu Gln 65 Asn Pro Glu Cys Ala Glu Thr Pro 100 Ala Asp Tyr Glu</pre> | 66 Artific ORMATION 4 Leu Leu 5 Cys Ile Leu Glu Ser His Leu Gly 70 Glu Ser 85 Asn Ser Glu Leu | : Syn Val Gly Lys Lys Leu Glu Arg | Leu Tyr Asn 40 Gly Cys Leu Asn Glu 120 | Leu His 25 Val Lys Ser Gly 105 Gln | Cys 10 Ala Thr Leu Lys 90 Thr Leu | Ala Asn Val Cys Ala 75 Lys Cys Ser | Leu Asn Thr Arg 60 Gly Ser Tyr Ser | Ser His 45 Leu Trp Pro Val 125 | Thr 30 Ser Lys Ile Ser Gly 110 Ser | 15 Asp Val Gly Leu Tyr Tyr Ser | Thr Asn Ile Gly 80 Ile Phe Phe |

-continued

| Phe | Tyr | Arg | Asn | Leu 165 | Leu | Trp | Leu | Thr | Glu 170 | Lys | Asn | Gly | Ser | - | Pro |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Asn | Leu | Ser | Lys 180 | | Tyr | Val | Asn | Asn 185 | | Glu | Lys | Glu | Val 190 | 175 Leu | Val |
| Leu | Trp | Gly 195 | | His | His | Pro | Ser 200 | | Ile | Gly | Asp | Gln 205 | | Thr | Ile |
| Tyr | Arg 210 | | Glu | Asn | Ala | Tyr 215 | | Ser | Val | Val | Ser 220 | | Asn | Tyr | Asn |
| Arg 225 | Arg | Phe | Thr | Pro | Glu 230 | | Ala | Lys | Arg | Pro 235 | | Val | Arg | Aab | Gln 240 |
| | Gly | Arg | Ile | Asn 245 | | Tyr | Trp | Thr | Leu 250 | | Glu | Pro | Gly | Asp 255 | |
| Ile | Ile | Phe | Glu 260 | | Asn | Gly | Asn | Leu 265 | | Ala | Pro | Trp | Tyr 270 | | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ser |
| Met | Asp 290 | Glu | Суз | Asp | Thr | Lys 295 | Сув | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Val | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Cys 320 |
| Pro | Lys | Tyr | Val | Arg 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | ГЛа | Glu | Phe | Asn 415 | Lys |
| Leu | Glu | Lys | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Lys | Ser | Gln | Leu 470 | Lys | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| САа | Phe | Glu | Phe | Tyr 485 | His | Lys | Суз | Asn | Asn 490 | Glu | Суз | Met | Glu | Ser 495 | Val |
| Lys | Asn | Gly | Thr 500 | Tyr | Asp | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn | Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln | Ile 530 | Leu | Ala | Ile | Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val 545 | Ser | Leu | Gly | Ala | Ile 550 | Ser | Phe | Trp | Met | Сув 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln | Суз | Arg | Ile | Сув 565 | Ile | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

<210> SEQ ID NO 5 <211> LENGTH: 566 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic polypeptide <400> SEQUENCE: 5 Met Lys Ala Lys Leu Leu Val Leu Leu Cys Thr Phe Thr Ala Thr Asp Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys Gly Ile Ala Pro Leu Gln Leu Gly Asn Cys Ser Ile Ala Gly Trp Ile Leu Gly 65 70 75 80 Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile Val Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp Phe Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr Val Thr Lys Gly Val Thr Ala Ala Cys Ser His Ala Gly Lys Ser Ser Phe Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys Asn Gly Ser Tyr Pro Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Gly Lys Glu Val Leu Val Leu Trp Gly Val His His Pro Ser Asn Ile Gly Asp Gln Gln Ala Leu Tyr Gln Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser His Tyr Asn Arg Lys Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val Arg Asp Gln Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser Asn Ala Ser 275 280 285 Met His Glu Cys Asp Thr Lys Cys Gln Thr Pro Gln Gly Ala Ile Asn Ser Ser Leu Pro Phe Gln Asn Ile His Pro Val Thr Ile Gly Glu Cys Pro Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Val Thr Gly Leu Arg Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly Tyr

-continued

| His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser 370 110 Thr Gln Asn Ala Ile Asn Gly Ile Thr Asn Lys Val Asn Ser Val Ile 390 110 Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn Lys 400 111 Leu Glu Lys Arg Met Glu Asn Leu Asn Lys Lys Uys Val Asp Asp Gly Phe 420 111 Leu Aug Thr Eur Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn 445 112 Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Ann Leu Tyr Glu 450 112 Lys Val Lys Ser Glu Leu Lys Asn Asn Ala Lys Glu The Gly Asn Gly 470 475 Cys Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met Glu Ser Val 480 480 Cys Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met Glu Ser Val 485 480 Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 510 540 Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met Gly Val Tyr 515 550 Call Ser Leu Gly Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530 550 Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cya Ser Asn Gly Ser Leu 545 560 Cillo SEQ ID NO 6 511 551 Cillo SEQUENCE: 6 55 50 Met Lys Ala Lys Leu Leu Val Leu Leu Cyo Ala Phe Thr Ala Thr Asp 1 51 Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20 51 Ala Phr Ya Leu Glu | His | | | | | | | | | | | | | | | |
|---|--|---------------------------------------|--|---|---|---|--|--|---|--|--|---|---|--|---|---|
| 385 390 395 400 Glu Lys Met Am Thr Gln Phe Mr Al, Va Val Gly Lys Glu Phe Am Lys Val Van Am Cly Van Am Cly Van Val Am Am Cly Am Am Am Clu Van Val Van Am Am Clu Am | | | Gln | Asn | Glu | Gln | | Ser | Gly | Tyr | Ala | | Asp | Gln | Lys | Ser |
| 405 410 413 Leu Ru 142 420 10 400 <td< td=""><td></td><td>Gln</td><td>Asn</td><td>Ala</td><td>Ile</td><td></td><td>Gly</td><td>Ile</td><td>Thr</td><td>Asn</td><td></td><td>Val</td><td>Asn</td><td>Ser</td><td>Val</td><td></td></td<> | | Gln | Asn | Ala | Ile | | Gly | Ile | Thr | Asn | | Val | Asn | Ser | Val | |
| 420425430Leu Asp Ile Trp Thr Tyr Am Ala Glu Leu Leu Val Leu Leu Glu Asm 440445Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asm Leu Tyr Glu 450460Lys Val Lys Ser Gln Leu Lys Asm Asn Ala Lys Glu Ile Gly Asm Gly 470470Cys Phe Glu Phe Tyr His Lys Cys Asm Asn Glu Cys Met Glu Ser Val 480480Cys Phe Glu Phe Tyr His Lys Cys Asm Asn Glu Cys Met Glu Ser Lys Leu 510500Asm Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met Gly Val Tyr 515515Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530525Gln Cys Arg Ile Cys Ile 565550c210> SEQ ID NO 6 c211> LENOTH: 566c221> Tyre Pret Pret 2023 OTHER INFORMATION: Synthetic polypeptidec400> SEQUENCE: 6Met Lys Ala Lys Leu Glu Lys Asm Asm Asm Ser Thr Asp Thr 20Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asm Asm Ser Thr Asp Thr 20Asp Thr Val Leu Glu Lys Asm Val Thr Val Thr His Ser Val Asm 40La Asp Thr Val Leu Glu Lys Asm Val Thr Val Thr His Ser Val Asm 40Leu Lue Glu Lys Cys Ser Ile Ala Gly Tyr Ile Leu Gly 70Ash Pro Leu Gln Leu Gly Lys Cys Ser Ile Ala Gly Trp Ile Leu Gly 80Ash Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Tyr Ser Tyr 80Ala Asp Thr Yal Leu Glu Lys Asm Clys Ser Trp Ser Tyr 80Ash Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr 80Ash Pro Glu Cys Glu Ser Cys Ser The Asp Thr 80Asp Thr Val Leu Glu Lys Asm Clys Ser Trp Ser Tyr 80Asp Thr Val Leu Glu Lys Asm Clys Ser Trp Ser Tyr 80Asp Thr Call Cys Glu Ser Leu Leu Ser Lys Lys Ser TrpSo | Glu | Lys | Met | Asn | | Gln | Phe | Thr | Ala | | Gly | Lys | Glu | Phe | | Lys |
| 435 440 445 Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lye Asn Leu Tyr Glu 455 Asp Can Leu Tyr Glu Lye Val Lye Ser Gln Leu Vs Asn Ash Ale Lye Glu Glu Glu Ser Val Asp Glu Tyr Ser Glu Glu Her Tyr His Lye Vs Asn Asn Ale Lye Glu Cse Net Glu Ser Val Asp Tyr Ser Glu Glu Ser Val Asp Tyr Ser Sis Ser Val Ser Ser Val Ser Val Tyr Sis Thr Val Ala Ser Ser Leu Val Leu Leu Sis Ser Ser Ser Val Ser Ser Ser Val Ser Val Ser Ser Ser Ser Ser Val Ser Val Ser Val Ser Ser Ser Ser Val Ser Val Ser Val Ser Ser Ser Ser Val Ser Val Ser Val Ser Ser Ser Ser Val Ser Val Ser Val Ser Ser Ser Ser Val Ser Val Ser Val Ser Ser Ser Ser Val No Ser Val Ser Val Ser Val | Leu | Glu | Lys | - | Met | Glu | Asn | Leu | | Lys | Lys | Val | Asp | - | Gly | Phe |
| 450455460Lyg Val Lyg Ser Gln Leu Lyg Agn Agn Ala Lyg Glu Ile Gly Agn Gly 465460Cyg Phe Glu Phe Tyr His Lyg Cyg Agn Agn Glu Cyg Met Glu Ser Val 485Lyg Agn Gly Thr Tyr Agp Tyr Pro Lyg Tyr Ser Glu Glu Ser Lyg Leu 500Agn Arg Glu Lyg Ile Agn Gly Val Lyg Leu Glu Ser Met Gly Val Tyr 515Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cyg Ser Agn Gly Ser Leu 555Cln Cyg Arg Ile Cyg Ile 565<210> SEQ ID No 6 <212> TYPE: PET <223> OTHER INFORMATION: Synthetic polypeptide<400> SEQUENCE: 6Met Lyg Ala Lyg Leu Glu Lyg Agn Val Thr Val Ala Agn Agn Ser Thr Agp Thr 20Ala Agp Thr Ile Cyg Ile Gly Tyr His Ala Agn Agn Ser Thr Agp Thr 20Val Agn Thr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 40Agn Thr 20Val Agn Thr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 45Agn Phr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 40Agn Phr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 40Ala Agn Thr Ile Cyg Ile Gly Tyr His Ala Agn Agn Ser Thr Agp Thr 20Val Agp Thr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 40Ala Agn Thr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Val Agn 40Ala Por Leu Glu Leu Glu Lyg Ser Ti Ser Tyr Ile 90Agn Phr Val Leu Glu Lyg Agn Chi Thr Val Thr His Ser Thr Agn 70Ala Agn Thr Val Leu Glu Lyg Agn Val Thr Val Thr His Ser Thr Agn 70Ala Agn Thr Val Leu Glu Lyg Agn Chi Thr Val Thr His Ser Val Agn 45Ala Agn Thr Val Leu Glu Lyg Agn Chi Lyg Lyg Ser TrAgn Phr Val Leu Glu Lyg Agn Ch | Leu | Asp | | Trp | Thr | Tyr | Asn | | Glu | Leu | Leu | Val | | Leu | Glu | Asn |
| 465470475480Cys Phe Glu Phe Tyr His Lys Cys Asn Aan Glu Cys Met Glu Ser Val 485490495480Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 500505Tyr Ser Glu Glu Ser Met Gly Val Tyr 522Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met Gly Val Tyr 515505Ser Leu Val Leu Leu 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 565560Gln Cys Arg Ile Cys Ile 565550550<210> SEQ ID NO 6 <211> LENGTH: S66<211> LENGTH: S66<212> TYPE: PRT <223> OTHER INFORMATION: Synthetic polypeptide<400> SEQUENCE: 6Met Lys Ala Lys Leu Glu Lys Ann Val Thr Val An Asn Ser Thr Asp 1Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp 30Val Asp Thr Val Leu Glu Lys Asn Gly Lys Leu Cys Lys Leu Lys Gly Ile 60Ala Pro Leu Gln Leu Gly Lys Cys Ser Ile Ala Gly Trp Ile Leu Gly 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Leu Lys Gly Trp Trp Try 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Leu Lys Gly Trp Try 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Leu Lys Gly Trp Try 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Leu Cys Lys Leu Gly Asp 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile 80Asn Pro Glu Cys Glu Ser Leu Cys Lys Ser Trp Ser Tyr Ile 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile 80Asn Pro Glu Cys Glu Ser Leu Leu | Glu | - | Thr | Leu | Asp | Phe | | Asp | Ser | Asn | Val | - | Asn | Leu | Tyr | Glu |
| 485490495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 500Tyr Sor Glu Glu Ser Lys Leu 510Lys Leu Glu Ser Met Gly Val Tyr 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 545Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 560<210> SEQ ID NO 6 <211> LENGTH: 566<211> SEQ ID NO 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence to Sequence<220> FEATURE: <223> OTHER INFORMATION: Synthetic polypeptide<400> SEQUENCE: 6Met Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Phe Thr Ala Thr Asp 1Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn 40Ala Pro Leu Glu Asp Ser His Asn Gly Lys Leu Cys Lys Leu Lys Gly Ile 50Ala Pro Leu Glu Leu Gly Lys Cys Ser Ile Ala Gly Tyr Ile Leu Gly 80Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Lys Ser Trp Ser Tyr Ile 95Ala Asp Tyr Glu Glu Leu Arg Glu Glu Leu Ser Ser Typ Pro Gly Asp Phe 110Ala Asp Tyr Glu Glu Leu Arg Glu Glu Leu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Glu Glu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Glu Glu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Glu Glu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Glu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Glu Ser Ser Trp Pro Asn His Thr 120Ala Asp Tyr Glu Glu Leu Arg Se | | Val | Lys | Ser | Gln | | Lys | Asn | Asn | Ala | | Glu | Ile | Gly | Asn | - |
| Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met Gly Val Tyr 515 S15 Sis | Суз | Phe | Glu | Phe | | His | Lys | Cys | Asn | | Glu | Суз | Met | Glu | | Val |
| 515 520 525 Gln Ile Leu Al Ile Tyr Ser Thr Val Ser Leu Val Leu Leu Leu Val Ser Leu Glu Al Ile Sr Phe Tyr Ser Ser Asn Glu Ser Leu Leu Val Ser Leu Glu Al Ile Ser Phe Tyr Met Cyr Asn Glu Ser Leu Leu C210> SEQ ID No 6 Ser Ser <td>Lys</td> <td>Asn</td> <td>Gly</td> <td></td> <td>Tyr</td> <td>Asp</td> <td>Tyr</td> <td>Pro</td> <td></td> <td>Tyr</td> <td>Ser</td> <td>Glu</td> <td>Glu</td> <td></td> <td>Lys</td> <td>Leu</td> | Lys | Asn | Gly | | Tyr | Asp | Tyr | Pro | | Tyr | Ser | Glu | Glu | | Lys | Leu |
| 530 535 540 Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 560 Gln Cys Arg Ile Cys Ile 555 Ser Asn Gly Ser Leu 560 Gln Cys Arg Ile Cys Ile 565 Ser Asn Gly Ser Leu 560 Ser Leu 7195 Ser Leu 565 <211> LENGTH: 566 Ser Phe Trp Met Cys Ala Ser China Sequence Ser Control Ser Seq ID NO 6 <212> TYPE: PRT Ser Asn Gly Ser Hei Asn 700 Ser Ser Asn Gly Ser Asn 700 <220> FEATURE: Ser This Artificial Sequence Ser Seq Control Ser Asn 700 Ser Ser Asn 700 <400> SEQUENCE: 6 Ser This Asn 700 Ser Thi Asp 700 Ser Thi Asp 700 Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thi Asp 700 Ser 700 Ser Asn 619 Ser 700 Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn 450 Ser 700 Ser 700 Ser 700 Ser 700 Ala Pro Leu Glu Asp Ser His Asn Gly Lys Leu Cys Lys Lys Leu Lys Gly The 80 Ser 700 Ser 700 Ser 700 Ser 700 Ser 700 Ser 700 Ala Pro Leu Glu Lys Gly Lys Leu Leu Ser Lys Lys Lys Ser Tip 800 Ser 700 Ser 70 | Asn | Arg | | Lys | Ile | Asp | Gly | | Lys | Leu | Glu | Ser | | Gly | Val | Tyr |
| 545 550 555 560 Gln Cys Arg Ile Cys Ile 565 555 560 <210> SEQ ID NO 6 <211> LENGTH: 566 <213> ORGANISM: Artificial Sequence <223> OTHER INFORMATION: Synthetic polypeptide <400> SEQUENCE: 6 Met Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Phe Thr Ala Thr Asp 15 15 Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20 30 Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn 450 55 Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Lys Leu Lys Gly Ile 60 60 Ala Pro Leu Gln Leu Gly Lys Cys Ser Ile Ala Gly Trp Ile Leu Gly 80 80 Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Lys Ser Trp Ser Tyr 11e 95 80 Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Lys Ser Trp Ser Tyr 11e 95 95 Val Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp Phe 110 110 Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Trp Pro Asn His Thr 120 120 Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Trp Pro Asn His Thr 130 120 Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Trp Pro Asn His Thr 130 140 Yal Thr Lys Gly | Gln | | Leu | Ala | Ile | Tyr | | Thr | Val | Ala | Ser | | Leu | Val | Leu | Leu |
| <pre><pre><pre><210 > SEQ ID NO 6 <211 > LENGTH: 566 <212 > TYPE: PRT <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <223 > OTHER INFORMATION: Synthetic polypeptide <400 > SEQUENCE: 6 Met Lys Ala Lys Leu Leu Val Leu Cys Ala Phe Thr Ala Thr Asp 1 5 10 10 11 Asp Thr Ala Thr Asp 1 20 25 11 Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20 21 Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn 40 40 45 11 Asp Thr Ser Val Asn 40 11 Asp Thr Val Leu Gly Lys Cys Ser II Ala Gly Trp II Leu Gly 60 Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr II Ser 40 Asp Thr Ofly Cys Gly Ser II Ala Gly Tyr Pro Gly Asp Phe 10 10 10 10 10 10 10 10 10 10 10 10 10 1</pre></pre></pre> | | Ser | Leu | Gly | Ala | | Ser | Phe | Trp | Met | | Ser | Asn | Gly | Ser | |
| <pre><211> LENGTH: 566 <212> TTPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <2223> OTHER INFORMATION: Synthetic polypeptide <400> SEQUENCE: 6 Met Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Phe Thr Ala Thr Asp 1 5 10 10 11 15 15 Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20 25 20 20 20 20 20 20 20 20 20 20 20 20 20</pre> | Gln | Суз | Arg | Ile | | Ile | | | | | | | | | | |
| MetLysAlaLysLeuLeuValLeuCysAlaPheThAlaThAspAlaAspThrIleCysIleGlyTyrHisAlaAsnAsnSerThrAspThrAlaAspThrIleCysIleGlyTyrHisAlaAsnAsnSerThrAspThrValAspThrValLeuGluLysAspValThrValThrHisSerValAsnLeuAspThrValLeuGluLysAspGlyThrValThrHisSerValAsnLeuLeuGluAspSerHisAspGlyLysCysLusGlyIspLusGlyIspAspThrLeuGluAspSerHisAspCysGlyLusGlyLusGlyIspAspThrLeuGlyLeuGlyCysCysCysGlyLusGlyIspIspIspIspIspAspThrGluCysGlyLeuLeuCysCysLusLusGlyIsp< | <213 <213 <213 <220 | 1> LH 2> TY 3> OF 0> FH | ENGTH PE: RGANI EATUF | I: 50 PRT SM: RE: | 56 Art: | | | - | | - 1 | | | | | | |
| 1 5 10 15 Ala Asp Thr Ile Cys Ile Gly Tyr $\frac{1}{25}$ Ala Asn Ser Thr Asp Thr Val Asp Thr Ile Cys Ile Gly Tyr $\frac{1}{25}$ Ala Asn Ser Thr Asp Thr Val Asp Thr Ile Cys Asn Asn Asn Ser Thr Asp Leu Asp Thr Asp Ser His Asp Gly Lys Ile Cys Isp Leu Lys Gly Isp Isp Gly Isp Isp Isp Ile Isp | <400 |)> SE | QUEN | ICE · | | | | | - | OTAF | pept | ide | | | | |
| 20 25 30 Val Asp Th Val Leu Glu Lys Asn Asn Val Thr Val Thr His Ser Val Asn Leu Leu Glu Asp Ser His Asn Glu Lys Asn Glu Thr Val Thr His Ser Val Asn Ala Pro Leu Glu Asp Ser His Asp Cys Lys Leu Lys Glu Thr His Ser Val Asn Ala Pro Leu Glu Leu Gly Lys Cys Lys Lys Gly Lys Gly Ist Gly Ser Ist Mas Gly Ser Ist Ser Try Ist Gly Ser Ist Ser Ist Ser Ser Ist Ser Ser </td <td></td> <td>Lys</td> <td></td> <td>юш.</td> <td>6</td> <td></td> <td></td> <td></td> <td>-</td> <td>στλΈ</td> <td>pept:</td> <td>ide</td> <td></td> <td></td> <td></td> <td></td> | | Lys | | юш. | 6 | | | | - | στλΈ | pept: | ide | | | | |
| 35 40 45 Leu Glu Asp Ser His Asp Gly Lys Lys Lys Lys Lys Lys Gly Lys Gly Ile Ala Pro Leu Glu Leu Gly Lys Cys Ser Ile Ala Ala Trp Ile Luc Gly Ser Ile Ala Ala Trp Ile Luc Gly Ser Ile Ala Ala Trp Ile Luc Gly Ser Ile Ala Ala Trp Ile Gly Gly Ser Ser Ser Ile Ala Ser Ser Trp Ser Gly Ser Ser< | | | Ala | | Leu | Leu | Val | Leu | | Суз | | | Thr | Ala | | Asp |
| 505560Ala 65ProLeu GlnLeu 70Cys SerIle Ala AsGly TrpTrpIle Leu B0Gly B0Asn Asn ProGlu Cys SetCys SerLeu Leu Leu SerLys Lys Lys Lys SerTrpIle Leu B0Gly B0Val Glu Glu Thr TrpPro Asn Asn SerGlu Asn Asn Clu B100Ser Ser Leu Leu Ser SerTrp Ser Trp Ser Trp Trp Ser Trp Ser Trp | Ala | Asp | | Lys Ile | Leu 5 | | | | Leu His | Cys 10 | Ala | Phe | | Thr | 15 | |
| 65 70 75 80 Asn Pro Glu Cys Glu Ser Leu Leu Ser Lys Lys Ser Trp Ser Tyr Ile 90 Ser Trp Ser Tyr Ile Val Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp Phe 110 Phe Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe 125 Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp 140 Pro Asn His Thr Val Thr Lys Gly Val Thr Ala Ala Cys Ser His Ala Gly Lys Ser Ser | | | Thr Thr | Lys Ile 20 | Leu 5 Cys | Ile | Gly | Tyr Asn | Leu His 25 | Cys 10 Ala | Ala Asn | Phe Asn | Ser His | Thr 30 | 15 Asp | Thr |
| 85 90 95 Val Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp Phe 100 100 Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe 115 Ser Phe 120 Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr 130 Nan His Thr 140 Val Thr Lys Gly Val Thr Ala Ala Cys Ser His Ala Gly Lys Ser Ser | Val | Asp Leu | Thr Thr 35 | Lys Ile 20 Val | Leu 5 Cys Leu | Ile Glu | Gly Lys Asn | Tyr Asn 40 | Leu His 25 Val | Cys 10 Ala Thr | Ala Asn Val | Phe Asn Thr Lys | Ser His 45 | Thr 30 Ser | 15 Asp Val | Thr Asn |
| 100105110Ala AspTyr Glu Glu Leu ArgGlu Gln Leu SerSerVal SerSerPhe115120120120125125125Glu ArgPheGlu IlePheProLysGlu SerSerTrpProAsnHisThr130135135140140140140140140140140ValThrLysGlyValThrAlaAlaCysSerHisAlaGlyLysSerSer | Val Leu Ala | Asp Leu 50 | Thr Thr 35 Glu | Lys Ile 20 Val Asp | Leu 5 Cys Leu Ser | Ile Glu His Gly | Gly Lys Asn 55 | Tyr Asn 40 Gly | Leu His 25 Val Lys | Cys 10 Ala Thr Leu | Ala Asn Val Cys Ala | Phe Asn Thr Lys 60 | Ser His 45 Leu | Thr 30 Ser Lys | 15 Asp Val Gly | Thr Asn Ile Gly |
| 115 120 125 Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr 130 135 140 Val Thr Lys Gly Val Thr Ala Ala Cys Ser His Ala Gly Lys Ser Ser | Val Leu Ala 65 | Asp Leu 50 Pro | Thr Thr 35 Glu Leu | Lys Ile 20 Val Asp Gln | Leu 5 Leu Ser Leu Glu | Ile Glu His Gly 70 | Gly Lys Asn 55 Lys | Tyr Asn 40 Gly Cys | Leu His 25 Val Lys Ser | Cys 10 Ala Thr Leu Ile | Ala Asn Val Cys Ala 75 | Phe Asn Thr Lys 60 Gly | Ser His 45 Leu Trp | Thr 30 Ser Lys Ile | 15 Asp Val Gly Leu Tyr | Thr Asn Ile Gly 80 |
| 130 135 140 Val Thr Lys Gly Val Thr Ala Ala Cys Ser His Ala Gly Lys Ser Ser | Val Leu Ala 65 Asn | Asp Leu 50 Pro Pro | Thr 35 Glu Leu Glu | Lys Ile 20 Val Asp Gln Cys Pro | Leu 5 Cys Leu Ser Leu Glu 85 | Ile Glu His Gly 70 Ser | Gly Lys Asn 55 Lys Leu | Tyr Asn 40 Gly Cys Leu | Leu His 25 Val Lys Ser Ser Gly | Cys 10 Ala Thr Leu Ile Lys 90 | Ala Asn Val Cys Ala 75 Lys | Phe Asn Thr Lys 60 Gly Ser | Ser 45 Leu Trp Trp | Thr 30 Ser Lys Ile Ser Gly | 15 Asp Val Gly Leu Tyr 95 | Thr Asn Ile Gly 80 Ile |
| | Val Leu Ala 65 Asn Val | Asp Leu 50 Pro Pro Glu | Thr Thr 35 Glu Leu Glu Thr Tyr | Lys Ile 20 Val Asp Gln Cys Pro 100 | Leu 5 Cys Leu Ser Leu Glu 85 Asn | Ile Glu His Gly 70 Ser Ser | Gly Lys Asn 55 Lys Leu Glu | Tyr Asn 40 Gly Cys Leu Asn Glu | Leu His 25 Val Lys Ser Ser Gly 105 | Cys 10 Ala Thr Leu Ile Lys 90 Thr | Ala Asn Val Cys Ala 75 Lys Cys | Phe Asn Thr Lys 60 Gly Ser Tyr | Ser His 45 Leu Trp Trp Pro Val | Thr 30 Ser Lys Ile Ser Gly 110 | 15 Asp Val Gly Leu Tyr 95 Asp | Thr Asn Ile Gly 80 Ile Phe |
| 145 150 155 160 | Val Leu Ala 65 Asn Val Ala | Asp Leu 50 Pro Glu Asp | Thr Thr 35 Glu Leu Glu Thr Tyr 115 | Lys Ile 20 Val Asp Gln Cys Pro 100 Glu | Leu 5 Cys Leu Ser Leu 6lu 85 Asn Glu | Ile Glu His Gly 70 Ser Ser Leu | Gly Lys Asn 55 Lys Leu Glu Arg Pro | Tyr Asn 40 Gly Cys Leu Asn Glu 120 | Leu His 25 Val Lys Ser Ser Gly 105 Gln | Cys 10 Ala Thr Leu Ile Lys 90 Thr Leu | Ala Asn Val Cys Ala 75 Lys Cys Ser | Phe Asn Thr Lys 60 Gly Ser Tyr Ser Trp | Ser His 45 Leu Trp Pro Val 125 | Thr 30 Ser Lys Ile Ser Gly 110 Ser | 15 Asp Val Gly Leu Tyr 95 Asp Ser | Thr Asn Ile Gly 80 Ile Phe Phe |

-continued

| Phe | Tyr | Arg | Asn | Leu 165 | Leu | Trp | Leu | Thr | Glu 170 | Lys | Asn | Gly | Ser | Tyr 175 | Pro |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Asn | Leu | Ser | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Glu | Lys | Glu | Val 190 | Leu | Val |
| Leu | Trp | Gly 195 | Val | His | His | Pro | Ser 200 | Asn | Ile | Gly | Asp | Gln 205 | Arg | Ala | Leu |
| Tyr | His 210 | Thr | Glu | Asn | Ala | Tyr 215 | Val | Ser | Val | Val | Ser 220 | Ser | His | Tyr | Asn |
| Arg 225 | Arg | Phe | Thr | Pro | Glu 230 | Ile | Ala | Lys | Arg | Pro 235 | ГÀЗ | Val | Arg | Asp | Gln 240 |
| Glu | Gly | Arg | Ile | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Ile | Phe | Glu 260 | Ala | Asn | Gly | Asn | Leu 265 | Ile | Ala | Pro | Trp | Tyr 270 | Ala | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ser |
| Met | Asp 290 | Glu | Сүз | Asp | Ala | Lys 295 | Сүз | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Val | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Сув 320 |
| Pro | Lys | Tyr | Val | Arg 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | ГЛа | Glu | Phe | Asn 415 | Lys |
| Leu | Glu | Arg | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lya | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | | Lys | Ser | Gln | Leu 470 | | Asn | Asn | Ala | Lys 475 | | Ile | Gly | Asn | Gly 480 |
| | Phe | Glu | Phe | Tyr 485 | | Lys | Суз | Asn | Asn 490 | | Суз | Met | Glu | Ser 495 | |
| LYa | Asn | Gly | Thr 500 | | Aap | Tyr | Pro | Lys 505 | | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn | Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | | Leu | Glu | Ser | Met 525 | | Val | Tyr |
| Gln | | | Ala | Ile | Tyr | | | Val | Ala | Ser | | | Val | Leu | Leu |
| | 530 Ser | Leu | Gly | Ala | | 535 Ser | Phe | Trp | Met | - | 540 Ser | Asn | Gly | Ser | |
| 545 Gln | Cys | Arg | Ile | Cys | 550 Ile | | | | | 555 | | | | | 560 |
| | - | 5 | | 565 | | | | | | | | | | | |

| | 0> SI 1> LI | | | | | | | | | | | | | | |
|------------|----------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| | 2 > T | | | | | | | | | | | | | | |
| | 3 > OI | | | Art: | ific: | ial S | Seque | ence | | | | | | | |
| <22 | 0> FI 3> O' | EATU | RE: | | | | - | | poly | oept: | ide | | | | |
| < 40 | 0> SI | equei | NCE : | 7 | | - | | - | | | | | | | |
| Met 1 | Lys | Ala | Lys | Leu 5 | Leu | Val | Leu | Leu | Cys 10 | Thr | Phe | Thr | Ala | Thr 15 | Asp |
| Ala | Asp | Thr | Ile 20 | Суз | Ile | Gly | Tyr | His 25 | Ala | Asn | Asn | Ser | Thr 30 | Asp | Thr |
| Val | Asp | Thr 35 | Val | Leu | Glu | Lys | Asn 40 | Val | Thr | Val | Thr | His 45 | Ser | Val | Asn |
| Leu | Leu 50 | Glu | Asp | Ser | His | Asn 55 | Gly | Lys | Leu | Суз | Arg 60 | Leu | Lys | Gly | Ile |
| Ala 65 | Pro | Leu | Gln | Leu | Gly 70 | Asn | Сүз | Ala | Ile | Ala 75 | Gly | Trp | Ile | Leu | Gly 80 |
| Asn | Pro | Glu | Суз | Glu 85 | Ser | Leu | Leu | Ser | Lys 90 | Lys | Ser | Trp | Ser | Tyr 95 | Ile |
| Val | Glu | Thr | Pro 100 | Asn | Ser | Glu | Asn | Gly 105 | Thr | Суз | Tyr | Pro | Gly 110 | Asp | Phe |
| Ile | Asp | Tyr 115 | Glu | Glu | Leu | Arg | Glu 120 | Gln | Leu | Ser | Ser | Val 125 | Ser | Ser | Phe |
| Glu | Arg 130 | Phe | Glu | Ile | Phe | Pro 135 | Lys | Glu | Ser | Ser | Trp 140 | Pro | Asn | His | Ala |
| Val 145 | Thr | Lys | Gly | Val | Thr 150 | Ala | Ala | Сув | Ser | His 155 | Ala | Gly | Lys | Ser | Ser 160 |
| Phe | Tyr | Arg | Asn | Leu 165 | Leu | Trp | Leu | Thr | Glu 170 | Lys | Asn | Gly | Ser | Tyr 175 | Pro |
| Asn | Leu | Ala | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Gly | Lys | Glu | Val 190 | Leu | Val |
| Leu | Trp | Gly 195 | Val | His | His | Pro | Ser 200 | Asn | Ile | Gly | Asp | Gln 205 | Gln | Ala | Leu |
| Tyr | Gln 210 | Thr | Glu | Asn | Ala | Tyr 215 | Val | Ser | Val | Val | Ser 220 | Ser | His | Tyr | Asn |
| Arg 225 | ГЛа | Phe | Thr | Pro | Glu 230 | Ile | Ala | Lys | Arg | Pro 235 | ГЛа | Val | Arg | Asp | Gln 240 |
| Glu | Gly | Arg | Ile | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Ile | Phe | Glu 260 | Ala | Asn | Gly | Asn | Leu 265 | Ile | Ala | Pro | Trp | Tyr 270 | Ala | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ala |
| Met | His 290 | Glu | Сүз | Asp | Thr | Lys 295 | Cys | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Ile | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Суз 320 |
| Pro | Lys | Tyr | Val | Arg 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His | Gln | Asn | Glu | Gln | Glv | Ser | Glv | Tvr | Ala | Ala | Asp | Gln | Ivs | Ser |

His His Gln As
n Glu Gln Gly Ser Gly Tyr Ala Ala As
p Gln Lys Ser $% \left({{\left({{{\left({{{\left({{{}}} \right)} \right)}} \right)}} \right)} \right)$

-continued

| 370 | | | | | | | | | | | | | | |
|--|---|--|--|---|--|--|--|---|---|---|--|---|--|--|
| 370 | | | | | 375 | | | | | 380 | | | | |
| Thr Gln 385 | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | Lys | Glu | Phe | Asn 415 | Lys |
| Leu Glu | Lys | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys Val 465 | Lys | Ser | Gln | Leu 470 | Lys | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| Cys Phe | Glu | Phe | Tyr 485 | His | Lys | Суз | Asn | Asn 490 | Glu | Суз | Met | Glu | Ser 495 | Val |
| Lys Asn | Gly | Thr 500 | Tyr | Asp | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln Ile 530 | Leu | Ala | Ile | Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val Ser 545 | Leu | Gly | Ala | Ile 550 | Ser | Phe | Trp | Met | Сув 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln Cys | Arg | Ile | Cys 565 | Ile | | | | | | | | | | |
| <210> S <211> L | ENGTE | | | | | | | | | | | | | |
| | YPE : RGANI EATUI | H: 50 PRT ISM: RE: | 56 Art: | | | - | | poly | pept: | ide | | | | |
| <211> Li <212> T <213> Oi <220> F | YPE : RGANI EATUI FHER | H: 50 PRT ISM: RE: INFO | 56 Art: DRMAT | | | - | | poly | pept: | ide | | | | |
| <211> Li <212> T <213> Oi <220> F <223> Oi | YPE : RGANI EATUI THER EQUEI | H: 50 PRT ISM: RE: INFO NCE: | Art: DRMA: 8 | FION | : Syr | nthet | ic p | | _ | | Ala | Ala | Thr 15 | Asp |
| <211> L <212> T <213> O <220> F <223> O <400> S Met Lys | YPE: RGANI EATUH THER EQUEI Ala | H: 56 PRT ISM: RE: INF(NCE: Arg | 56 Art: DRMA 8 Leu 5 | rion Leu | : Syr Val | Leu | tic <u>p</u> Leu | Cys 10 | Ala | Leu | | | 15 | |
| <211> L <212> T <213> O <220> F <223> O <400> S Met Lys 1 | YPE: RGANI EATUH THER EQUEN Ala Thr | H: 56 PRT ISM: RE: INF(NCE: Arg Ile 20 | Art: DRMA 8 Leu 5 Cys | Leu Ile | : Syr Val Gly | Leu Tyr | Leu His 25 | Cys 10 Ala | Ala Asn | Leu Asn | Ser | Thr 30 | 15 Asp | Thr |
| <211> L: <212> T <213> O <220> F <223> O <400> S: Met Lys 1 Ala Asp | YPE: RGANI EATUH FHER EQUEN Ala Thr Thr 35 | H: 56 PRT ISM: RE: INF(NCE: Arg Ile 20 Val | Art: DRMAT 8 Leu 5 Cys Leu | Leu Ile Glu | : Syr Val Gly Lys | Leu Tyr Asn 40 | Leu His 25 Val | Cys 10 Ala Thr | Ala Asn Val | Leu Asn Thr | Ser His 45 | Thr 30 Ser | 15 Asp Val | Thr Asn |
| <211> L: <212> T <213> O' <220> F <223> O' <400> S: Met Lys 1 Ala Asp Val Asp Leu Leu | YPE: RGANI EATUH FHER EQUEN Ala Thr Thr 35 Glu | H: 56 PRT ISM: ISM: RE: INFC NCE: Arg 11e 20 Val Asp | 56 Art: 8 Leu 5 Cys Leu Ser | Leu Ile Glu His | : Syr Val Gly Lys Asn 55 | Leu Tyr Asn 40 Gly | Leu His 25 Val Lys | Cys 10 Ala Thr Leu | Ala Asn Val Cys | Leu Asn Thr Arg 60 | Ser His 45 Leu | Thr 30 Ser Lys | 15 Asp Val Gly | Thr Asn Ile |
| <pre><211> Li <212> T <213> OU <220> F <223> OU <400> S Met Lys 1 Ala Asp Val Asp Leu Leu 50 Ala Pro</pre> | YPE: RGANI EATUH HER EQUE Ala Thr 35 Glu Leu | H: 56 PRT ISM: RE: INFC NCE: Arg Ile 20 Val Asp Gln | Art: DRMA: 8 Leu 5 Cys Leu Ser Leu | Leu Ile Glu His Gly 70 | : Syr Val Gly Lys Asn 55 Lys | Leu Tyr Asn 40 Gly Cys | Leu His 25 Val Lys Asn | Cys 10 Ala Thr Leu Ile | Ala Asn Val Cys Ala 75 | Leu Asn Thr Arg 60 Gly | Ser His 45 Leu Trp | Thr 30 Ser Lys Ile | 15 Asp Val Gly Leu | Thr Asn Ile Gly 80 |
| <211> L: <212> T <213> O' <220> F <223> O' <400> S: Met Lys 1 Ala Asp Val Asp Leu Leu 50 Ala Pro 65 | YPE: RGAN: EATUI THER EQUEI Ala Thr 35 Glu Leu Glu | H: 56 PRT ISM: CE: INFC VCE: Arg Ile 20 Val Asp Gln Cys | Art: DRMA: 8 Leu 5 Cys Leu Ser Leu Glu 85 | Leu Ile Glu His Gly 70 Ser | : Syn Val Gly Lys Asn 55 Lys Leu | Leu Tyr Asn Gly Cys Leu | Leu His 25 Val Lys Asn Ser | Cys 10 Ala Thr Leu Ile Asn 90 | Ala Asn Val Cys Ala 75 Arg | Leu Asn Thr Arg 60 Gly Ser | Ser 45 Leu Trp Trp | Thr 30 Ser Lys Ile Ser | 15 Asp Val Gly Leu Tyr 95 | Thr Asn Ile Gly 80 Ile |
| <pre><211> L: <212> T <213> O' <220> F <223> O' <400> S: Met Lys 1 Ala Asp Val Asp Leu Leu 50 Ala Pro 65 Asn Pro</pre> | YPE: RGANI EATUDI FHER Ala Thr Ala Thr 35 Glu Leu Glu Thr | H: 56 PRT LSM: RE: INFC NCE: Arg Ile 20 Val Asp Gln Cys Pro 100 | Art: Art: 8 Leu 5 Cys Leu Ser Leu Glu 85 Asn | IION Leu Ile Glu His Gly 70 Ser Ser | : Syr Val Gly Lys Lys Lys Leu Glu | Leu Tyr Asn Gly Cys Leu Asn | Leu His 25 Val Lys Asn Ser Gly 105 | Cys 10 Ala Thr Leu Ile Asn 90 Thr | Ala Asn Val Cys Ala 75 Arg Cys | Leu Asn Thr Arg 60 Gly Ser Tyr | Ser His 45 Leu Trp Trp Pro | Thr 30 Ser Lys Ile Ser Gly 110 | 15 Asp Val Gly Leu Tyr 95 Asp | Thr Asn Ile Gly 80 Ile Phe |
| <211> L: <212> T <213> O' <220> F <223> O' <400> S: Met Lys 1 Ala Asp Val Asp Leu Leu 50 Ala Pro 65 Asn Pro Val Glu | YPE: RGANI EATUDI HER EQUEN Ala Thr Thr 35 Glu Leu Glu Thr Thr Thr 115 | H: 56 PRT ISM: ISM: ISM: RE: INFC VCE: Arg 20 Val Asp Gln Cys Pro 100 Glu | Art: Art: 8 Leu 5 Cys Leu Ser Leu 85 Asn Glu | TION Leu Ile Glu His Gly 70 Ser Ser Leu | : Syr Val Gly Lys Lys Lys Leu Glu Arg | Leu Tyr Asn 40 Gly Leu Asn Glu 120 | Leu His 25 Val Lys Asn Ser Gly 105 Gln | Cys 10 Ala Thr Leu Ile Asn 90 Thr Leu | Ala Asn Val Cys Ala 75 Arg Cys Ser | Leu Asn Thr Arg 60 Gly Ser Tyr Ser | Ser His 45 Leu Trp Pro Val 125 | Thr 30 Ser Lys Ile Ser Gly 110 Ser | 15 Asp Val Gly Leu Tyr 95 Asp Ser | Thr Asn Ile Gly 80 Ile Phe |
| <pre><211> L: <212> T <213> O' <220> F <223> O' <400> S: Met Lys 1 Ala Asp Val Asp Leu Leu 50 Ala Pro 65 Asn Pro Val Glu Ile Asp Glu Arg</pre> | YPE:: RGANI EATUN FLER Ala Thr Ala Thr Thr 35 Glu Leu Glu Thr Tyr 115 Phe | H: 56 PRT (SM: RE: INFC NCE: Arg 20 Val Asp Gln Cys Gln Cys Dro 100 Glu Glu | 56 Art: DRMA: 8 Leu 5 Cys Leu Ser Leu Glu 85 Asn Glu Ile | TION Leu Ile Glu His Gly 70 Ser Ser Leu Phe | : Syr Val Gly Lys Lys Lys Glu Arg Pro 135 | Leu Tyr Asn 40 Gly Cys Leu Asn Glu 120 Lys | Leu His 25 Val Lys Asn Ser Gly 105 Gln Glu | Cys 10 Ala Thr Leu Ile Asn 90 Thr Leu Ser | Ala Asn Val Cys Ala 75 Arg Cys Ser Ser | Leu Asn Thr Arg 60 Gly Ser Tyr Ser Ser Trp 140 | Ser His 45 Leu Trp Pro Val 125 Pro | Thr 30 Ser Lys Ile Ser Gly 110 Ser Lys | 15 Asp Val Gly Leu Tyr 95 Asp Ser His | Thr Asn Ile Gly 80 Ile Phe Phe Asn |

-continued

| | | | | 165 | | | | | 170 | | | | | 175 | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Asn | Leu | Ser | Asn 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Gly | Lys | Glu | Val 190 | Leu | Val |
| Leu | Trp | Gly 195 | Val | His | His | Pro | Ser 200 | Asn | Ile | Asp | Asp | Gln 205 | Gln | Thr | Leu |
| Tyr | Gln 210 | Lys | Glu | Asn | Ala | Tyr 215 | Val | Ser | Val | Val | Ser 220 | Ser | Asn | Tyr | Asn |
| Arg 225 | Arg | Phe | Thr | Pro | Glu 230 | Ile | Ala | Glu | Arg | Pro 235 | Lys | Val | Arg | Gly | Gln 240 |
| Ala | Gly | Arg | Met | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Ile | Phe | Glu 260 | Ala | Asn | Gly | Asn | Leu 265 | Ile | Ala | Pro | Trp | Tyr 270 | Ala | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ser |
| Met | His 290 | Glu | Суз | Asp | Thr | Lys 295 | Суз | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Ile | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Суз 320 |
| Pro | Lys | Tyr | Val | Arg 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | ГЛа | Glu | Phe | Asn 415 | Asn |
| Leu | Glu | Lys | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Lys | Ser | Gln | Leu 470 | Arg | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| | Phe | Glu | Phe | Tyr 485 | His | Lys | Cys | Asp | Asn 490 | | Суз | Met | Glu | Ser 495 | |
| Lys | Asn | Gly | Thr 500 | | Asp | Tyr | Pro | Lys 505 | | Ser | Glu | Glu | Ser 510 | | Leu |
| Asn | Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln | Ile 530 | | Ala | Ile | Tyr | Ser 535 | | Val | Ala | Ser | Ser 540 | | Val | Leu | Leu |
| | | Leu | Gly | Ala | Ile | | Phe | Trp | Met | - | | Asn | Gly | Ser | |
| 545 Gln | Cys | Arg | Ile | | 550 Ile | | | | | 555 | | | | | 560 |
| | | | | 565 | | | | | | | | | | | |

| ~ 21 | l> LI | NGTI | y. 5 | 66 | | | | | | | | | | | |
|------------|----------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| <212 | 2> T? | YPE : | PRT | | | | | | | | | | | | |
| | 3> 0H)> FI | | | Art: | ific: | ial S | Seque | ence | | | | | | | |
| | | | | ORMA | FION | : Syı | nthe | cic p | poly | pept | ide | | | | |
| <400 |)> SI | EQUEI | NCE : | 9 | | | | | | | | | | | |
| Met 1 | Lys | Ala | Lys | Leu 5 | Leu | Val | Leu | Leu | Cys 10 | Ala | Phe | Thr | Ala | Thr 15 | Asp |
| Ala | Asp | Thr | Ile 20 | Суз | Ile | Gly | Tyr | His 25 | Ala | Asn | Asn | Ser | Thr 30 | Asp | Thr |
| Val | Aab | Thr 35 | Val | Leu | Glu | Lys | Asn 40 | Val | Thr | Val | Thr | His 45 | Ser | Val | Asn |
| Leu | Leu 50 | Glu | Asp | Ser | His | Asn 55 | Gly | Lys | Leu | Cys | Arg 60 | Leu | Lys | Gly | Ile |
| Ala 65 | Pro | Leu | Gln | Leu | Gly 70 | Asn | Суз | Ser | Ile | Ala 75 | Gly | Trp | Ile | Leu | Gly 80 |
| Asn | Pro | Glu | Cys | Glu 85 | Ser | Leu | Phe | Ser | Lys 90 | Lys | Ser | Trp | Ser | Tyr 95 | Ile |
| Ala | Glu | Thr | Pro 100 | Asn | Ser | Glu | Asn | Gly 105 | Thr | Сүз | Tyr | Pro | Gly 110 | Tyr | Phe |
| Ala | Asb | Tyr 115 | Glu | Glu | Leu | Arg | Glu 120 | Gln | Leu | Ser | Ser | Val 125 | Ser | Ser | Phe |
| Glu | Arg 130 | Phe | Glu | Ile | Phe | Pro 135 | Lys | Glu | Ser | Ser | Trp 140 | Pro | Asn | His | Thr |
| Val 145 | Thr | Lys | Gly | Val | Thr 150 | Ala | Ser | Суз | Ser | His 155 | Lys | Gly | Lys | Ser | Ser 160 |
| Phe | Tyr | Arg | Asn | Leu 165 | Leu | Trp | Leu | Thr | Glu 170 | Lys | Asn | Gly | Ser | Tyr 175 | Pro |
| Asn | Leu | Ser | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Glu | Lys | Glu | Val 190 | Leu | Val |
| Leu | Trp | Gly 195 | Val | His | His | Pro | Ser 200 | Asn | Ile | Gly | Asp | Gln 205 | Arg | Ala | Ile |
| Tyr | His 210 | Thr | Glu | Asn | Ala | Tyr 215 | Val | Ser | Val | Val | Ser 220 | Ser | His | Tyr | Asn |
| Arg 225 | Arg | Phe | Thr | Pro | Glu 230 | Ile | Ala | ГЛЗ | Arg | Pro 235 | ГЛЗ | Val | Arg | Asp | Gln 240 |
| Glu | Gly | Arg | Ile | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Ile | Phe | Glu 260 | Ala | Asn | Gly | Asn | Leu 265 | Ile | Ala | Pro | Trp | Tyr 270 | Ala | Phe |
| Ala | Leu | Ser 275 | Arg | Gly | Phe | Gly | Ser 280 | Gly | Ile | Ile | Thr | Ser 285 | Asn | Ala | Ser |
| Met | Asp 290 | Glu | Суз | Asp | Ala | Lys 295 | Суз | Gln | Thr | Pro | Gln 300 | Gly | Ala | Ile | Asn |
| Ser 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Val | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Сув 320 |
| Pro | Гла | Tyr | Val | Arg 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Val | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |

-continued

| Thr 385 | Gln | Asn | Ala | Ile | Asn 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
|---|--|--|--|---|---|--|---|---|--|--|--|--|--|--|---|
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | Lys | Glu | Phe | Asn 415 | Lys |
| Leu | Glu | Arg | Arg 420 | Met | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Asp | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Lys | Ser | Gln | Leu 470 | Lys | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| СЛа | Phe | Glu | Phe | Tyr 485 | His | Lys | Суз | Asn | Asn 490 | Glu | Суз | Met | Glu | Ser 495 | Val |
| ГЛа | Asn | Gly | Thr 500 | Tyr | Asp | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn | Arg | Glu 515 | Lys | Ile | Asp | Gly | Val 520 | Lys | Leu | Glu | Ser | Met 525 | Gly | Val | Tyr |
| Gln | Ile 530 | Leu | Ala | Ile | Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val 545 | Ser | Leu | Gly | Ala | Ile 550 | Ser | Phe | Trp | Met | Сув 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln | Сув | Arg | Ile | Сув 565 | Ile | | | | | | | | | | |
| <21 | | | | | | | | | | | | | | | |
| <21 <21 <21 <22 | 1> LI 2> TY 3> OH 0> FI 3> OY | YPE : RGANI EATUI | H: 50 PRT ISM: RE: | Art: | | | - | | poly | pept: | ide | | | | |
| <21: <21: <21: <22: <22: | 1> LI 2> TY 3> OF 0> FI | YPE: RGANI EATUI THER | H: 50 PRT ISM: RE: INFO | Art: DRMA | | | - | | poly | pept: | ide | | | | |
| <21: <21: <21: <22: <22: <40 | 1> LI 2> TY 3> OF 0> FI 3> OY | YPE : RGANI EATUI THER EQUEI | H: 50 PRT ISM: RE: INFO NCE: | Art: DRMA 10 | rion (| : Syı | nthet | ic p | | _ | | Ala | Ala | Thr 15 | Asn |
| <21: <21: <22: <22: <22: <400 Met 1 | 1> LI 2> T 3> OI 0> FI 3> O 0> SI | YPE: RGANI EATUH THER EQUEN Ala | H: 50 PRT ISM: RE: INF(NCE: Ile | Art: DRMA 10 Leu 5 | TION Leu | : Syn Val | nthet Leu | tic p Leu | Суз 10 | Thr | Phe | | | 15 | |
| <21: <21: <22: <22: <22: <40 Met 1 Ala | 1> L1 2> T 3> OF 0> F1 3> O 3> O 0> SI Lys | YPE: RGANI EATUH THER EQUEN Ala Thr | H: 56 PRT ISM: RE: INFO NCE: Ile Leu 20 | Art: DRMA 10 Leu 5 Cys | IION Leu Ile | : Syn Val Gly | Leu Tyr | Leu His 25 | Cys 10 Ala | Thr Asn | Phe Asn | Ser | Thr 30 | 15 Asp | Thr |
| <21: <21: <22: <22: <400 Met 1 Ala Val | 1 > LI 2 > T 3 > OI 0 > FI 3 > O 0 > SI Lys Asp | YPE: RGANI EATUR THER EQUER Ala Thr Thr 35 | H: 56 PRT ISM: RE: INF(NCE: Ile Leu 20 Val | Art: DRMA 10 Leu 5 Cys Leu | IION Leu Ile Glu | : Syı Val Gly Lys | Leu Tyr Asn 40 | Leu His 25 Val | Cys 10 Ala Thr | Thr Asn Val | Phe Asn Thr | Ser His 45 | Thr 30 Ser | 15 Asp Val | Thr Asn |
| <211 <211 <222 <222 <400 Met 1 Ala Val Leu | 1 > LI 2 > T 3 > OF 0 > FI 3 > O 0 > SI Lys Asp Asp | YPE: RGANI EATUI THER SQUEI Ala Thr Thr 35 Glu | H: 56 PRT ISM: ISM: RE: INFC NCE: Ile Leu 20 Val Asp | Art: DRMA 10 Leu 5 Cys Leu Lys | Leu Ile Glu His | : Syr Val Gly Lys Asn 55 | Leu Tyr Asn 40 Gly | Leu His 25 Val Lys | Cys 10 Ala Thr Leu | Thr Asn Val Cys | Phe Asn Thr Lys 60 | Ser His 45 Leu | Thr 30 Ser Lys | 15 Asp Val Gly | Thr Asn Ile |
| <211 <212 <221 <222 <400 Met 1 Ala Val Leu Ala 65 | <pre>1> LL 2> TTT 3> OD 5> FH 3> OT 0> SD Lys Asp Asp Leu 50</pre> | YPE: RGANI EATUH FHER EQUEN Ala Thr 35 Glu Leu | H: 56 PRT ISM: ISM: INFC NCE: INFC NCE: ILeu 20 Val Asp His | Art: 10 Leu 5 Cys Leu Lys Leu | TION Leu Ile Glu His Gly 70 | : Syn Val Gly Lys Asn 55 Lys | Leu Tyr Asn 40 Gly Cys | Leu His 25 Val Lys Asn | Cys 10 Ala Thr Leu Ile | Thr Asn Val Cys Ala 75 | Phe Asn Thr Lys 60 Gly | Ser His 45 Leu Trp | Thr 30 Ser Lys Leu | 15 Asp Val Gly Leu | Thr Asn Ile Gly 80 |
| <211 <211 <221 <222 <400 Met 1 Ala Val Leu Ala 65 Asn | 1> LJ 2> TY 3> OI 0> FI 3> O 0> SI Lys Asp Leu 50 Pro | YPE: CGAN: EATUI THER EQUEI Ala Thr Ala Thr 35 Glu Leu Glu | H: 56 PRT ISM: RE: INFC NCE: Ile Leu 20 Val Asp His Cys | Art: DRMA: 10 Leu 5 Leu Lys Leu Glu 85 | TION Leu Ile Glu His Gly 70 Leu | : Syn Val Gly Lys Asn 55 Lys Leu | Leu Tyr Asn Gly Cys Leu | Leu His 25 Val Lys Asn Thr | Cys 10 Ala Thr Leu Ile Ala 90 | Thr Asn Val Cys Ala 75 Ser | Phe Asn Thr Lys 60 Gly Ser | Ser His 45 Leu Trp Trp | Thr 30 Ser Lys Leu Ser | 15 Asp Val Gly Leu Tyr 95 | Thr Asn Ile Gly 80 Ile |
| <21: <21: <22: <22: <22: <400 Met 1 Ala Val Leu Ala 65 Asn Val | 1> L1 2> TT 3> OD D> FH 3> O D> SI Lys Asp Asp Leu 50 Pro | YPE: CGAN: EATUU FHER SQUEI Ala Thr 35 Glu Leu Glu Thr | H: 54 PRT ISM: RE: INFC NCE: Ile Leu 20 Val Asp His Cys Ser 100 | Art: 10 Leu 5 Cys Leu Lys Leu Glu 85 Asn | TION Leu Ile Glu His Gly 70 Leu Ser | : Syn Val Gly Lys Lys Lys Leu Asp | Leu Tyr Asn Gly Leu Asn | Leu His 25 Val Lys Asn Thr Gly 105 | Cys 10 Ala Thr Leu Ile Ala 90 Thr | Thr Asn Val Cys Ala 75 Ser Cys | Phe Asn Thr 60 Gly Ser Tyr | Ser His 45 Leu Trp Trp Pro | Thr 30 Ser Lys Leu Ser Gly 110 | 15 Asp Val Gly Leu Tyr 95 Asp | Thr Asn Ile Gly 80 Ile Phe |
| <21: <21: <22: <22: <22: <22: <20: Ala Val Leu Ala 65 Asn Val Ile | 1> L1 2> TT 3> OD 0> FF 3> O Lys Asp Asp Leu 50 Pro Glu | YPE: RGAN: EATUI FHER EQUEN Ala Thr Thr 35 Glu Leu Glu Thr Thr Thr 115 | H: 54 PRT ISM: ISM: ISM: RE: INFC NCE: Ile Leu 20 Val Asp His Cys Ser 100 Glu | Art: 10 Leu 5 Cys Leu Lys Leu 6 lu 85 Asn Glu | TION Leu Ile Glu His Gly 70 Leu Ser Leu | : Syn Val Gly Lys Lys Lys Leu Asp Arg | Leu Tyr Asn 40 Gly Leu Asn Glu 120 | Leu His 25 Val Lys Asn Thr Gly 105 Gln | Cys 10 Ala Thr Leu Ile Ala 90 Thr Leu | Thr Asn Val Cys Ala 75 Ser Cys Ser Ser | Phe Asn Thr Lys 60 Gly Ser Tyr Ser | Ser His 45 Leu Trp Trp Pro Val | Thr 30 Ser Lys Leu Ser Gly 110 Ser | 15 Asp Val Gly Leu Tyr 95 Asp Ser | Thr Asn Ile Gly 80 Ile Phe Phe |
| <pre><21: <21: <21: <22: <22: <22: <400 Met 1 Ala Val Leu Ala 65 Asn Val Ile Glu</pre> | 1> LH 2> TT 3> OI 0> FF 3> O 0> SI Lys Asp Asp Pro Pro Glu Asp | YPE: RGAN: EATUDI FHER GQUET Ala Thr Thr 35 Glu Leu Glu Thr Tyr 115 Phe | H: 54 PRT ISM: RE: INFC NCE: Ile Leu 20 Val Asp His Cys Ser 100 Glu Glu | Art: 10 Leu 5 Cys Leu Lys Leu 6 Glu 85 Asn Glu 11e | TION Leu Ile Glu His Gly 70 Leu Ser Leu Phe | : Syn Val Gly Lys Lys Leu Asp Arg Pro 135 | Leu Tyr Asn 40 Cys Leu Asn Glu 120 Lys | Leu His 25 Val Lys Asn Thr Gly 105 Gln Thr | Cys 10 Ala Thr Leu Ile Ala 90 Thr Leu Ser | Thr Asn Val Cys Ala 75 Ser Cys Ser Ser Ser | Phe Asn Thr Lys 60 Gly Ser Tyr Ser Tyr Ser Trp 140 | Ser His 45 Leu Trp Pro Val 125 Pro | Thr 30 Ser Lys Leu Ser Gly 110 Ser Asn | 15 Asp Val Gly Leu Tyr 95 Asp Ser His | Thr Asn Ile Gly 80 Ile Phe Phe Glu |
| <pre><21: <21: <21: <22: <22: <22: <22: <22:</pre> | 1> L1 2> TT 3> OI 0> FI 3> O Lys Asp Asp Leu 50 Pro Glu Asp Arg 130 | YPE:: CGANUI EATUI FHER EQUEN Ala Thr Thr 35 Glu Leu Glu Thr Tyr 115 Phe Lys | H: 54 PRT ISM: RE: IINFC NCE: ILeu 20 Val Asp His Cys Ser 100 Glu Glu Gly | Art: DRMA' 10 Leu Lys Leu Glu Glu Ile Val | TION Leu Ile Glu His Gly 70 Leu Ser Leu Phe Thr 150 | : Syn Val Gly Lys Lys Lys Leu Asp Arg Pro 135 Ala | Leu Tyr Asn 40 Gly Cys Leu Asn Glu 120 Lys Ala | Leu His 25 Val Lys Asn Thr Gly 105 Gln Thr Cys | Cys 10 Ala Thr Leu Ile Ala 90 Thr Leu Ser Pro | Thr Asn Val Cys Ala 75 Ser Cys Ser Ser Ser Tyr 155 | Phe Asn Thr Lys 60 Gly Ser Tyr Ser Trp 140 Ala | Ser His 45 Leu Trp Trp Pro Val 125 Pro Gly | Thr 30 Ser Lys Leu Ser Gly 110 Ser Asn Ala | 15 Asp Val Gly Leu Tyr Ssr Ser Ser | Thr Asn Ile Gly 80 Ile Phe Glu Ser 160 |

-continued

| Lys | Leu | Ser | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Gly | Lys | Glu | Val 190 | Leu | Val |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Leu | Trp | Gly 195 | Ile | His | His | Pro | Pro 200 | Thr | Ser | Thr | Asp | Gln 205 | Gln | Ser | Leu |
| Tyr | Gln 210 | Asn | Ala | Asp | Ala | Tyr 215 | Val | Phe | Val | Gly | Ser 220 | Ser | Lys | Tyr | Asn |
| Arg 225 | ГЛа | Phe | Lys | Pro | Glu 230 | Ile | Ala | Ala | Arg | Pro 235 | ГЛа | Val | Arg | Asp | Gln 240 |
| Ala | Gly | Arg | Met | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Ile | Glu | Pro | Gly | Asp 255 | Thr |
| Ile | Thr | Phe | Glu 260 | Ala | Thr | Gly | Asn | Leu 265 | Val | Val | Pro | Arg | Tyr 270 | Ala | Phe |
| Ala | Met | Asn 275 | Arg | Gly | Ser | Gly | Ser 280 | Gly | Ile | Ile | Ile | Ser 285 | Asp | Ala | Pro |
| Val | His 290 | Asp | Суз | Asn | Thr | Lys 295 | Сүз | Gln | Thr | Pro | Lүа 300 | Gly | Ala | Ile | Asn |
| Thr 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Ile | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Сув 320 |
| Pro | Lys | Tyr | Val | Lys 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Ala | Thr | Gly | Leu 335 | Arg |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser |
| Thr 385 | Gln | Asn | Ala | Ile | Asp 390 | Gly | Ile | Thr | Asn | Lys 395 | Val | Asn | Ser | Val | Ile 400 |
| Glu | Lys | Met | Asn | Thr 405 | Gln | Phe | Thr | Ala | Val 410 | Gly | ГЛЗ | Glu | Phe | Asn 415 | His |
| Leu | Glu | Lys | Arg 420 | Ile | Glu | Asn | Leu | Asn 425 | Lys | Lys | Val | Asp | Asp 430 | Gly | Phe |
| Leu | Asp | Ile 435 | Trp | Thr | Tyr | Asn | Ala 440 | Glu | Leu | Leu | Val | Leu 445 | Leu | Glu | Asn |
| Glu | Arg 450 | Thr | Leu | Aab | Phe | His 455 | Asp | Ser | Asn | Val | Lys 460 | Asn | Leu | Tyr | Glu |
| Lys 465 | Val | Arg | Ser | Gln | Leu 470 | LÀa | Asn | Asn | Ala | Lys 475 | Glu | Ile | Gly | Asn | Gly 480 |
| Суз | Phe | Glu | Phe | Tyr 485 | His | LÀa | Суз | Asp | Asp 490 | Thr | Суз | Met | Glu | Ser 495 | Val |
| ГЛЗ | Asn | Gly | Thr 500 | Tyr | Aab | Tyr | Pro | Lys 505 | Tyr | Ser | Glu | Glu | Ser 510 | Lys | Leu |
| Asn | Arg | Glu 515 | Glu | Ile | Asp | Gly | Val 520 | ГЛа | Leu | Glu | Ser | Thr 525 | Arg | Ile | Tyr |
| Gln | Ile 530 | Leu | Ala | Ile | Tyr | Ser 535 | Thr | Val | Ala | Ser | Ser 540 | Leu | Val | Leu | Leu |
| Val 545 | Ser | Leu | Gly | Ala | Ile 550 | Ser | Phe | Trp | Met | Суз 555 | Ser | Asn | Gly | Ser | Leu 560 |
| Gln | Сув | Arg | Ile | Сув 565 | Ile | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

<210> SEQ ID NO 11 <211> LENGTH: 566

-continued

| | 2> T 3> OH | | | Art | ific | ial : | Seque | ence | | | | | | | | |
|------------|----------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--|
| | 0> FI 3> 01 | | | ORMA | TION | : Syı | nthet | ic p | poly | pept: | ide | | | | | |
| <40 | 0> SI | EQUEI | ICE : | 11 | | | | | | | | | | | | |
| Met 1 | Lys | Ala | Ile | Leu 5 | Leu | Val | Leu | Leu | Cys 10 | Thr | Phe | Thr | Ala | Ala 15 | Asn | |
| Ala | Asp | Thr | Leu 20 | Суз | Ile | Gly | Tyr | His 25 | Ala | Asn | Asn | Ser | Thr 30 | Asp | Thr | |
| Val | Asp | Thr 35 | Val | Leu | Glu | Lys | Asn 40 | Val | Thr | Val | Thr | His 45 | Ser | Val | Asn | |
| Leu | Leu 50 | Glu | Asp | Arg | His | Asn 55 | Gly | Lys | Leu | Суз | Lys 60 | Leu | Gly | Gly | Ile | |
| Ala 65 | Pro | Leu | His | Leu | Gly 70 | Lys | Сүз | Asn | Ile | Ala 75 | Gly | Trp | Leu | Leu | Gly 80 | |
| Asn | Pro | Glu | Сүз | Glu 85 | Leu | Leu | Leu | Thr | Ala 90 | Ser | Ser | Trp | Ser | Tyr 95 | Ile | |
| Val | Glu | Thr | Ser 100 | Asn | Ser | Asp | Asn | Gly 105 | Thr | Суз | Tyr | Pro | Gly 110 | Asp | Phe | |
| Ile | Asn | Tyr 115 | Glu | Glu | Leu | Arg | Glu 120 | Gln | Leu | Ser | Ser | Val 125 | Ser | Ser | Phe | |
| Glu | Arg 130 | Phe | Glu | Ile | Phe | Pro 135 | Lys | Ala | Ser | Ser | Trp 140 | Pro | Asn | His | Glu | |
| Thr 145 | Asn | Arg | Gly | Val | Thr 150 | Ala | Ala | Сув | Pro | Tyr 155 | Ala | Gly | Ala | Asn | Ser 160 | |
| Phe | Tyr | Arg | Asn | Leu 165 | Ile | Trp | Leu | Val | Lys 170 | Lys | Gly | Asn | Ser | Tyr 175 | Pro | |
| Lys | Leu | Ser | Lys 180 | Ser | Tyr | Val | Asn | Asn 185 | Lys | Gly | ГЛЗ | Glu | Val 190 | Leu | Val | |
| Leu | Trp | Gly 195 | Ile | His | His | Pro | Pro 200 | Thr | Ser | Thr | Asp | Gln 205 | Gln | Ser | Leu | |
| Tyr | Gln 210 | Asn | Ala | Asp | Ala | Tyr 215 | Val | Phe | Val | Gly | Ser 220 | Ser | Lys | Tyr | Asn | |
| Arg 225 | Lys | Phe | Lys | Pro | Glu 230 | Ile | Ala | Ala | Arg | Pro 235 | Гла | Val | Arg | Gly | Gln 240 | |
| Ala | Gly | Arg | Met | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Leu | Glu | Pro | Gly | Asp 255 | Thr | |
| Ile | Thr | Phe | Glu 260 | Ala | Thr | Gly | Asn | Leu 265 | Val | Val | Pro | Arg | Tyr 270 | Ala | Phe | |
| Ala | Met | Asn 275 | Arg | Gly | Ser | Gly | Ser 280 | Gly | Ile | Ile | Ile | Ser 285 | Asp | Ala | Pro | |
| Val | His 290 | Aab | Cys | Asn | Thr | Lys 295 | Сүз | Gln | Thr | Pro | Lуя 300 | Gly | Ala | Ile | Asn | |
| Thr 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Ile | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Сув 320 | |
| Pro | Lys | Tyr | Val | Lys 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Ala | Thr | Gly | Leu 335 | Arg | |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly | |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr | |
| His | His 370 | Gln | Asn | Glu | Gln | Gly 375 | Ser | Gly | Tyr | Ala | Ala 380 | Asp | Gln | Lys | Ser | |
| | | | | | | | | | | | | | | | | |

continued

| -continued |
|--|
| Thr Gln Asn Ala Ile Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile 385 390 395 400 |
| Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His 405 410 415 |
| Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe 420 425 430 |
| Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Glu Asn 435 440 445 |
| Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Glu 450 455 460 |
| Lys Val Arg Ser Gln Leu Arg Asn Asn Ala Lys Glu Ile Gly Asn Gly 465 470 475 480 |
| Cys Phe Glu Phe Tyr His Lys Cys Asp Asp Thr Cys Met Glu Ser Val 485 490 495 |
| Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 500 505 510 |
| Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr 515 520 525 |
| Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530 535 540 |
| Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 545 550 555 560 |
| Gln Cys Arg Ile Cys Ile 565 |
| <pre><12> TYPE: PRT <213> ORCANISM: Artificial Sequence <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (4)(4) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (11)(13) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (11)(13) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (15)(16) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (20)(20) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (53)(53) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (53)(53) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (60)(60) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(61) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(62) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(62) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(62) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(62) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (62)(62)</pre> |
| <pre><223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (71)(71) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid</pre> |
| |

<220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (73)..(74) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (78)..(78) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (86)..(86) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (88)..(91) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (97)..(97) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (100) .. (100) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (102)..(103) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (111)..(111) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (113)..(114) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (137)..(137) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (142)..(142) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (144)..(147) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (152)..(152) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (154)..(156) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (158)..(159) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (166) .. (166) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (169)..(170) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (172)...(174) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (177)..(177) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (179)..(180)

-continued

| <220> | | | | | | | | |
|---|--|--|----------------------|---|--|--|---|--------------------------------------|
| <220> | OTHER INFORMATION: Xaa | can | be | anv | naturallv | occurring | amino | acid |
| | | | ~ ~ | ~~~ | nao ar ar rj | 0000111113 | | |
| | FEATURE: | | | | | | | |
| <221> | NAME/KEY: misc_feature | | | | | | | |
| <222> | LOCATION: (187)(187) | | | | | | | |
| | | | 1 | | | | | |
| | OTHER INFORMATION: Xaa | can | be | any | nacurally | occurring | amino | acia |
| <220> | FEATURE: | | | | | | | |
| < 221 > | NAME/KEY: misc_feature | | | | | | | |
| | | | | | | | | |
| | LOCATION: (196)(196) | | | | | | | |
| <223> | • OTHER INFORMATION: Xaa | can | be | any | naturally | occurring | amino | acid |
| | FEATURE: | | | - | - | | | |
| | | | | | | | | |
| <221> | • NAME/KEY: misc_feature | | | | | | | |
| <222> | LOCATION: (200)(203) | | | | | | | |
| | OTHER INFORMATION: Xaa | dan | ho | antz | naturally | occurring | amino | acid |
| | | can | be | any | nacurarry | occurring | amiiio | aciu |
| <220> | FEATURE: | | | | | | | |
| <221> | NAME/KEY: misc_feature | | | | | | | |
| | LOCATION: (206)(208) | | | | | | | |
| | | | | | | | | |
| <223> | • OTHER INFORMATION: Xaa | can | be | any | naturally | occurring | amino | acid |
| <220> | FEATURE: | | | | | | | |
| | | | | | | | | |
| | NAME/KEY: misc_feature | | | | | | | |
| <222> | LOCATION: (210)(213) | | | | | | | |
| < 223 > | OTHER INFORMATION: Xaa | can | be | anv | naturally | occurring | amino | acid |
| | FEATURE: | | | 2 | | •••• | | |
| | | | | | | | | |
| <221> | NAME/KEY: misc_feature | | | | | | | |
| < 2.2.2 > | LOCATION: (217)(217) | | | | | | | |
| | | ~ ~ ~ | ha | | mat | | | a a i d |
| | OTHER INFORMATION: Xaa | can | be | any | nacurally | occurring | amino | aciu |
| <220> | FEATURE: | | | | | | | |
| < 221 > | NAME/KEY: misc_feature | | | | | | | |
| | | | | | | | | |
| | LOCATION: (219)(219) | | | | | | | |
| <223> | • OTHER INFORMATION: Xaa | can | be | any | naturally | occurring | amino | acid |
| | FEATURE: | | | - | - | 0 | | |
| | | | | | | | | |
| <221> | • NAME/KEY: misc_feature | | | | | | | |
| <222> | LOCATION: (222)(222) | | | | | | | |
| | OTHER INFORMATION: Xaa | aan | ho | ant | naturally | occurring | amino | acid |
| | | Can | be | any | nacurarry | occurring | amiino | aciu |
| <220> | FEATURE: | | | | | | | |
| <221> | NAME/KEY: misc_feature | | | | | | | |
| | LOCATION: (224)(224) | | | | | | | |
| | | | | | | | | |
| <223> | • OTHER INFORMATION: Xaa | can | be | any | naturally | occurring | amino | acid |
| | FEATURE: | | | | | | | |
| | | | | | | | | |
| | • NAME/KEY: misc_feature | | | | | | | |
| <222> | LOCATION: (226)(226) | | | | | | | |
| -223- | OTHER INFORMATION: Xaa | can | he | anv | naturally | occurring | amino | acid |
| | | | ~ ~ | | nao ar ar rj | 00000222009 | | 4014 |
| <220> | FEATURE: | | | | | | | |
| <221> | NAME/KEY: misc_feature | | | | | | | |
| -222- | LOCATION: (228)(228) | | | | | | | |
| | | | | | | | | |
| <223> | OTHER INFORMATION: Xaa | can | | | | | | acid |
| <220> | | 00 | ne | any | nacurarry | Occurring | amiiio | 4014 |
| | FEATURE: | | be | any | nacurarry | Occurring | amiiio | 4014 |
| 001 | FEATURE: | oun | De | any | naculally | occurring | amiiio | |
| | NAME/KEY: misc_feature | oun | be | any | nacurarry | occurring | amino | |
| | | Jui | Je | any | nacurarry | occurring | amino | |
| <222> | <pre>NAME/KEY: misc_feature LOCATION: (233)(233)</pre> | | | - | - | _ | | |
| <222> <223> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa | | | - | - | _ | | |
| <222> <223> | <pre>NAME/KEY: misc_feature LOCATION: (233)(233)</pre> | | | - | - | _ | | |
| <222> <223> <220> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: | | | - | - | _ | | |
| <222> <223> <220> <221> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | | | - | - | _ | | |
| <222> <223> <220> <221> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) | can | be | any | naturally | occurring | amino | acid |
| <222> <223> <220> <221> <221> <222> <222> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa | can | be | any | naturally | occurring | amino | acid |
| <222> <223> <220> <221> <221> <222> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) | can | be | any | naturally | occurring | amino | acid |
| <222> <223> <220> <221> <222> <222> <223> <220> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: | can | be | any | naturally | occurring | amino | acid |
| <222> <223> <220> <221> <222> <222> <223> <220> <220> <221> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can | be | any | naturally | occurring | amino | acid |
| <222> <223> <220> <221> <222> <223> <220> <220> <221> <221> <221> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) | can can | be be | any | naturally | occurring | amino amino | acid acid |
| <222> <223> <220> <221> <222> <223> <220> <220> <221> <221> <221> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can | be be | any | naturally | occurring | amino amino | acid |
| <222> <223> <220> <221> <222> <223> <220> <220> <221> <221> <222> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa | can can | be be | any | naturally | occurring | amino amino | acid |
| <222> <223> <220> <221> <222> <223> <220> <221> <221> <222> <222> <223> <222> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: | can can | be be | any | naturally | occurring | amino amino | acid |
| <222> <223> <220> <221> <222> <223> <220> <221> <222> <222> <223> <222> <223> <220> <221> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can | be be | any | naturally | occurring | amino amino | acid |
| <222> <223> <220> <221> <222> <223> <220> <221> <220> <221> <223> <220> <222> <222> <222> <222> <222> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <222> <223> <220> <221> <222> <223> <220> <221> <220> <221> <223> <220> <222> <222> <222> <222> <222> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <222> <223> <220> <221> <222> <222> <223> <222> <222> <222> <222> <221> <222> <221> <222> <221> <222> <222> <222> <222> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <pre><222> <223> <220> <221> <221> <222> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <pre><222> <223> <220> <221> <221> <222> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <pre><222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <220> <20> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244). OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244). OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can can | be be | any any any | naturally naturally naturally | occurring occurring | amino amino amino | acid acid |
| <pre><222> <223> <220> <221> <223> <220> <221> <223> <220> <221> <222> <222> <221> <222> <222> <221> <222> <222> <221> <222> <222> <221> <222> <222> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <221> <221> <222> <222> <223> <220> <20> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <221> <221> <222> <222> <223> <220> <20> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <222> <223> <220> <221> <222> <223> <220> <222> <223> <220> <222> <223> <220> <222> <223> <220> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <221> <223> <220> <221> <223> <220> <221> <222> <223> <220> <221> <222> <222> <220> <221> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <221> <223> <220> <221> <223> <220> <221> <222> <223> <220> <221> <222> <222> <220> <221> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: | can can can can | be be be | any any any any | naturally naturally naturally naturally | occurring occurring occurring | amino amino amino | acid acid acid |
| <pre><222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <220> <221> <222> <220> <221> <220> <220> <221> <220> <220> <221> <220> <20> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) | can can can can | be be be | any any any any any | naturally naturally naturally naturally | occurring occurring occurring occurring | amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa | can can can can | be be be | any any any any any | naturally naturally naturally naturally | occurring occurring occurring occurring | amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) | can can can can | be be be | any any any any any | naturally naturally naturally naturally | occurring occurring occurring occurring | amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <221> <221> <222> <223> <220> <20> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: | can can can can | be be be | any any any any any | naturally naturally naturally naturally | occurring occurring occurring occurring | amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <222> <223> <220> <220> <221> <222> <223> <220> <221> <222> <222> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can can can | be be be | any any any any any | naturally naturally naturally naturally | occurring occurring occurring occurring | amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <222> <223> <220> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258) (258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258) (258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (268) (268) | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <222> <223> <220> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <223> <220> <221> <223> <220> <221> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <220> <221> <222> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <220> <221> <222> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <221> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa | can can can can can | be be be be | any any any any any any | naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (268)(268) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (266)(267) | can can can can can can | be be be be | any any any any any any any | naturally naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa | can can can can can can | be be be be | any any any any any any any | naturally naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <221> <222> <223> <223> <222> <223> <223> <222> <223> <23> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (254)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (266)(267) OTHER INFORMATION: Xaa | can can can can can can | be be be be | any any any any any any any | naturally naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233) (233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239) (239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241) (241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244) (244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251) (251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (253) (258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262) (262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262) (262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262) (262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (266) (267) OTHER INFORMATION: Xaa | can can can can can can | be be be be | any any any any any any any | naturally naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid acid |
| <pre><222> <223> <220> <221> <222> <222> <223> <220> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <223> <220> <221> <222> <</pre> | NAME/KEY: misc_feature LOCATION: (233)(233) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (239)(239) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (241)(241) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (244)(244) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (254)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (251)(251) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (258)(258) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (262)(262) OTHER INFORMATION: Xaa FEATURE: NAME/KEY: misc_feature LOCATION: (266)(267) OTHER INFORMATION: Xaa | can can can can can can | be be be be | any any any any any any any | naturally naturally naturally naturally naturally naturally | occurring occurring occurring occurring occurring occurring | amino amino amino amino amino | acid acid acid acid acid |

-continued

<222> LOCATION: (269)..(269) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (274)..(275) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (278)..(278) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (284)..(284) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (286)..(286) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (288)..(291) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (293)..(294) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (300) .. (300) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (305) .. (305) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature $<222 > LOCATION \cdot (312) (312)$ <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (325)..(325) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (332)..(332) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (390)..(390) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (416) .. (416) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (419)..(419) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (421)..(421) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (435)..(435) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (467)..(467) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (471)..(471) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (489)..(491) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <220> FEATURE:

| <222 | 2 > L(| CAT: | ION : | (51) | c_fea 6) TION | (516) |) | ı be | any | nati | ural | ly o | ccur: | rinq | amino | acid |
|------------|------------|------------|------------|------------|---------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------|
| | 0> FI | | | mia | c_fea | ture | | | - | | | - | | 5 | | |
| <222 | 2> L(| CAT: | ION: | (52 | 5) | (527) |) | | | | | | | | | |
| <223 | 3 > 0' | THER | INF | ORMA' | TION | : Xaa | a cai | n be | any | nati | iral: | ly o | ccur: | ring | amino | acid |
| <40 | 0> SI | EQUEI | NCE : | 12 | | | | | | | | | | | | |
| Met 1 | Lys | Ala | Xaa | Leu 5 | Leu | Val | Leu | Leu | Cys 10 | Xaa | Xaa | Xaa | Ala | Xaa 15 | Xaa | |
| Ala | Asp | Thr | Xaa 20 | Суз | Ile | Gly | Tyr | His 25 | Ala | Asn | Asn | Ser | Thr 30 | Asp | Thr | |
| Val | Asp | Thr 35 | Val | Leu | Glu | Lys | Asn 40 | Val | Thr | Val | Thr | His 45 | Ser | Val | Asn | |
| Leu | Leu 50 | Glu | Asp | Xaa | His | Asn 55 | Gly | Lys | Leu | Сүз | Xaa 60 | Leu | Хаа | Gly | Ile | |
| Ala 65 | Pro | Leu | Xaa | Leu | Gly 70 | Хаа | Сүз | Xaa | Xaa | Ala 75 | Gly | Trp | Xaa | Leu | Gly 80 | |
| Asn | Pro | Glu | Суз | Glu 85 | Хаа | Leu | Xaa | Хаа | Xaa 90 | Xaa | Ser | Trp | Ser | Tyr 95 | Ile | |
| Xaa | Glu | Thr | Xaa 100 | Asn | Xaa | Хаа | Asn | Gly 105 | Thr | Сүз | Tyr | Pro | Gly 110 | Хаа | Phe | |
| Xaa | Xaa | Tyr 115 | Glu | Glu | Leu | Arg | Glu 120 | Gln | Leu | Ser | Ser | Val 125 | Ser | Ser | Phe | |
| Glu | Arg 130 | Phe | Glu | Ile | Phe | Pro 135 | Lys | Хаа | Ser | Ser | Trp 140 | Pro | Хаа | His | Xaa | |
| Xaa 145 | Хаа | Хаа | Gly | Val | Thr 150 | Ala | Xaa | Суз | Хаа | Xaa 155 | Хаа | Gly | Хаа | Хаа | Ser 160 | |
| Phe | Tyr | Arg | Asn | Leu 165 | Хаа | Trp | Leu | Хаа | Xaa 170 | Lys | Хаа | Xaa | Хаа | Tyr 175 | Pro | |
| Хаа | Leu | Хаа | Xaa 180 | Ser | Tyr | Val | Asn | Asn 185 | ГЛЗ | Хаа | ГЛа | Glu | Val 190 | Leu | Val | |
| Leu | Trp | Gly 195 | Xaa | His | His | Pro | Xaa 200 | Xaa | Xaa | Хаа | Asp | Gln 205 | Хаа | Xaa | Хаа | |
| Tyr | Xaa 210 | Xaa | Xaa | Хаа | Ala | Tyr 215 | Val | Xaa | Val | Хаа | Ser 220 | Ser | Xaa | Tyr | Xaa | |
| Arg 225 | Xaa | Phe | Хаа | Pro | Glu 230 | Ile | Ala | Xaa | Arg | Pro 235 | ГЛЗ | Val | Arg | Xaa | Gln 240 | |
| Xaa | Gly | Arg | Xaa | Asn 245 | Tyr | Tyr | Trp | Thr | Leu 250 | Хаа | Glu | Pro | Gly | Asp 255 | Thr | |
| Ile | Хаа | Phe | Glu 260 | Ala | Хаа | Gly | Asn | Leu 265 | Хаа | Xaa | Pro | Xaa | Tyr 270 | Ala | Phe | |
| Ala | Хаа | Xaa 275 | Arg | Gly | Хаа | Gly | Ser 280 | Gly | Ile | Ile | Xaa | Ser 285 | Хаа | Ala | Xaa | |
| Хаа | Xaa 290 | Хаа | СЛа | Xaa | Хаа | Lys 295 | Сув | Gln | Thr | Pro | Xaa 300 | Gly | Ala | Ile | Asn | |
| Xaa 305 | Ser | Leu | Pro | Phe | Gln 310 | Asn | Xaa | His | Pro | Val 315 | Thr | Ile | Gly | Glu | Cys 320 | |
| Pro | Lys | Tyr | Val | Xaa 325 | Ser | Thr | Lys | Leu | Arg 330 | Met | Xaa | Thr | Gly | Leu 335 | Arg | |
| Asn | Ile | Pro | Ser 340 | Ile | Gln | Ser | Arg | Gly 345 | Leu | Phe | Gly | Ala | Ile 350 | Ala | Gly | |
| Phe | Ile | Glu 355 | Gly | Gly | Trp | Thr | Gly 360 | Met | Ile | Asp | Gly | Trp 365 | Tyr | Gly | Tyr | |

-continued

| His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser 370 Thr Gln Asn Ala Ile Xaa Gly Ile Thr Asn Lys Val Asn Ser Val Ile 385 Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn Xaa 400 Leu Glu Xaa Arg Xaa Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe |
|---|
| 385 390 395 400 Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn Xaa 405 410 Leu Glu Xaa Arg Xaa Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe |
| 405 410 415 Leu Glu Xaa Arg Xaa Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe |
| |
| 420 425 430 |
| Leu Asp Xaa Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn 435 440 445 |
| Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Glu 450 455 460 |
| Lys Val Xaa Ser Gln Leu Xaa Asn Asn Ala Lys Glu Ile Gly Asn Gly 465 470 475 480 |
| Cys Phe Glu Phe Tyr His Lys Cys Xaa Xaa Xaa Cys Met Glu Ser Val 485 490 495 |
| Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 500 505 510 |
| Asn Arg Glu Xaa Ile Asp Gly Val Lys Leu Glu Ser Xaa Xaa Xaa Tyr 515 520 525 |
| Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu 530 535 540 |
| Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 545 550 555 560 |
| Gln Cys Arg Ile Cys Ile 565 |
| <210> SEQ ID NO 13 <211> LENGTH: 1719 |
| <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagcttatga aggccaagct gctggtgctg ctgtgcgcct tcacagccac ctacgccgac 60 |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagcttatga aggccaagct gctggtgctg ctgtgcgcct tcacagccac ctacgccgac 60 accatctgca tcggctacca cgccaacaac agcaccgaca ccgtggatac cgtgctggaa 120 |
| <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagottatga aggocaagot gotggtgotg otgtgogoot toacagocaa otaogoogaa 60 accatotgoa toggotacca ogocaacaac agoacogaca cogtggatac ogtgotggaa 120 aagaacgtga cogtgacoca cagogtgaac otgotggaag atagocacaa oggoaagotg 180 |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagcttatga aggccaagct gctggtgctg ctgtgcgcct tcacagccac ctacgccgac 60 accatctgca tcggctacca cgccaacaac agcaccgaca ccgtggatac cgtgctggaa 120 aagaacgtga ccgtgaccca cagcgtgaac ctgctggaag atagccacaa cggcaagctg 180 tgccggctga agggaatcgc ccctctgcag ctggggcaact gctctatcgc cggctggatt 240</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacageeace etacgeegae 60 accatetgea teggetacea egecaacaae ageaeegaaa eegtggatae egtgetggaa 120 aagaaegtga eegtgaeee etgetggaae etgetggaag atageeacaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggatt 240 etgggeaace eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegae 60 accatetgea teggetaeca egecaacaae ageaeegaaa eegtggatae eggetggaa 120 aagaaegtga eegtgaeeea eagegtgaae etgetggaag atageeaaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggatt 240 etgggeaaee eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300 acceecaaca gegagaaegg eaeetgttae eeeggetaet tegeegaeta egaggaaetgg 360</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegaa for accatetgea teggetaeca egecaacaae ageaeegaaa eegtggatae egtgetggaa 120 aagaaegtga eegtgaeee eagegtgaae etgetggaag atagecaeaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggatt 240 etgggeaaee eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300 acceeeaaca gegagaaegg eaeetgttae eeeggetaet tegeegaeta egaggaaetgg 360 egggaacage tgageagegt gteeagette gagagatteg agattteee eaaagagage 420</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegae foo accatetgea teggetaeca egeegaacaa ageaeegaaa eegtggatae eggetggaa 120 aagaaegtga eegtgaeeea eagegtgaae etgetggaag atageeaaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggatt 240 etgggeaaee eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300 acceeeaaca gegagaaegg eacetgttae eeeggetaet tegeegaeta egaggaaetg 360 egggaacage tgageagegt gteeagette gagagatteg agattteee eaaagagage 420 agetggeeea accaeacegt gaeeaaagge gtgaeegeet eetgeteeca eaatggeaag 480</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegae 60 accatetgea teggetaeca egecaacaae ageaeegaea eegtggatae egtgetggaa 120 aagaaegtga eegtgaeee eagegtgaae etgetggaag atageeaeaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggat 240 etgggeaaee eegagaaegg gageetgtte ageaaagagt eetggteeta eategtggaa 300 acceeeaaea gegagaaegg eacetgttae eeeggetaeet tegeegaeta egaggaaetg 360 egggaaeage tgageagegt gteeagette gagagatteg agattteee eaaagagage 420 agetggeeea accaeeegt gaeeaagge gtgaeegeet eetgeteea eaatggeaag 480 ageagettet acagaaaeet getgtggetg acegagaaga aeggeageta eeeeaeegg 540</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegaa 120 aagaaegtga eegtgaeee ageeggaae etgetggaag atageeaeaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggatt 240 etgggeaaee eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300 acceeeaaa gegagaaegg eacetgtte gagagatteg agattteee caaaggagaet gageagegt deeggeaee eaagagage 420 agetggeeea eecaaeeegg gtgeeegeet eetgetgeeea eaagagage 420 agetggeeea eecaaeeegg gageetgte acegagaaga aeggeageta eecaaggaag 480 ageagettet acagaaaeet getgtggetg acegagaaga aeggeageta eeceaaeeg 540 ageaagaget aegtgaacaa caaagaaaaa gaggtgetgg tgetgtgggg egtgeaceae 600</pre> |
| <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic construct <400> SEQUENCE: 13 aagettatga aggecaaget getggtgetg etgtgegeet teacagecae etaegeegae 60 aceatetgea teggetaeca egecaacaae ageaeegaa atagecaeaa eggeaagetg 180 tgeeggetga agggaatege eeetetgeag etgggeaaet getetatege eggetggaat 240 etgggeaaee eegagtgega gageetgtte ageaaagagt eetggteeta eategtggaa 300 aceceeaaea gegagaaegg eacetgttae eeeggetaet tegeegaeta egaggaaeeg 360 egggaacage tgageagegt gteeagette gagagatteg agattteee eaaagagage 420 agetggecea aceaeaeegt gaceaaagge gtgaceget eetgeteee aaagagage 420 agetggecea aceaeaeegt gaceaaagge gtgaceget eetgeteee aaagagage 540 ageaagaettet acagaaaeet getgtggetg acegagaaga aeggeageta eeeaacetg 540 ageaagaget aegtgaacaa caaagaaaaa gaggtgetgg tgetgtgggg egtgeaeeae 600 eetageaaea teggegaeea gegggeeate taceaeeeg agaatgeeta egtgteegtg 660</pre> |
| <pre><213 > ORGANISM: Artificial Sequence <220 > FEATURE: <223 > OTHER INFORMATION: Synthetic construct <400 > SEQUENCE: 13 aagcttatga aggccaagct gctggtgctg ctgtgcgcct tcacagccac ctacgccgac 60 accatctgca tcggctacca cgccaacaac agcaccgaca ccgtggatac cgtgctggaa 120 aagaacgtga ccgtgaccca cagcgtgaac ctgctggaag atagccacaa cggcaagctg 180 tgccggctga agggaatege cectetgcag ctgggeaact getetatege eggetggat 240 ctggggcaace ccgagtgcga gagcetgtte agcaaagagt cetggtecta categtggaa 300 acceccaaca gcgagaacgg cacetgttac ecceggetact tegeegaeta egaggaactg 360 egggaacage tgagcaget gtecagette gagagatteg agatttee caaagagage 420 agetggecca accacaccgt gaccaaagge gtgaccgeet ectgetecca caatggcaag 480 agcagettet acagaaacet getgtggetg accgagaaga acggeageta ecceaaceg 540 agcaagaget acgtgaacaa caaagaaaaa gaggtgetgg tgetgtgggg egtgeaccac 600 ectagcaaca teggegacca gegggecate taccacaccg agaatgeet acgtgtecgtg 660 gtgtecagee actacagcag acggtteace ccegagateg ccaagaggee caaagtgegg 720</pre> |

US 9,580,475 B2

-continued

| cctcagggcg | ccatcaatag | cagcctgccc | ttccagaacg | tgcaccccgt | gaccatcggc | 960 | | |
|------------|------------|------------|------------|------------|------------|------|--|--|
| gagtgcccca | aatacgtgcg | gagcaccaag | ctgcggatgg | tcaccggcct | gagaaacatc | 1020 | | |
| cccagcatcc | agagcagggg | cctgttcgga | gccattgccg | gctttatcga | gggcggctgg | 1080 | | |
| accggcatga | tcgacgggtg | gtacggctat | caccaccaga | acgagcaggg | cagcggctac | 1140 | | |
| gccgccgatc | agaagtctac | ccagaacgcc | atcaacggca | tcaccaacaa | agtgaacagc | 1200 | | |
| gtgatcgaga | agatgaacac | ccagttcacc | gccgtgggca | aagagttcaa | caagctggaa | 1260 | | |
| cggcggatgg | aaaacctgaa | caagaaggtg | gacgacggct | tcctggacat | ctggacctac | 1320 | | |
| aacgccgaac | tgctggtgct | gctggaaaac | gagcggaccc | tggacttcca | cgacagcaac | 1380 | | |
| gtgaagaacc | tgtacgagaa | agtgaagtcc | cagctgaaga | acaacgccaa | agagatcggc | 1440 | | |
| aacggctgct | tcgagttcta | ccacaagtgc | aacaacgagt | gcatggaaag | cgtgaagaat | 1500 | | |
| ggcacctacg | actaccccaa | gtacagcgag | gaaagcaagc | tgaaccgcga | gaagatcgac | 1560 | | |
| ggcgtgaagc | tggaatccat | gggcgtgtac | cagatcctgg | ccatctatag | caccgtggcc | 1620 | | |
| agcagcctgg | tgctgctggt | gtctctgggc | gccatcagct | tttggatgtg | cagcaacggc | 1680 | | |
| agcctgcagt | gccggatctg | tatcggcagc | atcggatcc | | | 1719 | | |
| | | | | | | | | |

50

The invention claimed is:

1. A recombinant influenza hemagglutinin (HA) polypeptide comprising:

- (i) an amino acid sequence at least 99% identical to SEQ ³⁰ ID NO: 1, wherein the amino acid sequence of the polypeptide comprises no more than 5 amino acid substitutions relative to SEQ ID NO: 1;
- (ii) the amino acid sequence of SEQ ID NO: 2;
- (iii) an amino acid sequence at least 99% identical to SEQ ³⁵
 ID NO: 3, wherein the amino acid sequence of the polypeptide comprises no more than 6 amino acid substitutions relative to SEQ ID NO: 3;
- (iv) an amino acid sequence at least 99% identical to SEQ ID NO: 4, wherein the amino acid sequence of the ⁴⁰ polypeptide comprises no more than 8 amino acid substitutions relative to SEQ ID NO: 4;
- (v) an amino acid sequence at least 98% identical to SEQ ID NO: 5, wherein the amino acid sequence of the polypeptide comprises no more than 10 amino acid ⁴⁵ substitutions relative to SEQ ID NO: 5;
- (vi) an amino acid sequence at least 99% identical to SEQ ID NO: 6, wherein the amino acid sequence of the polypeptide comprises no more than 8 amino acid substitutions relative to SEQ ID NO: 6;
- (vii) an amino acid sequence at least 97% identical to SEQ ID NO: 7, wherein the amino acid sequence of the polypeptide comprises no more than 10 amino acid substitutions relative to SEQ ID NO: 7;

- (viii) an amino acid sequence at least 99% identical to SEQ ID NO: 8, wherein the amino acid sequence of the polypeptide comprises no more than 10 amino acid substitutions relative to SEQ ID NO: 8;
- (ix) the amino acid sequence of SEQ ID NO: 9;
- (x) an amino acid sequence at least 99% identical to SEQ ID NO: 10, wherein the amino acid sequence of the polypeptide comprises no more than 8 amino acid substitutions relative to SEQ ID NO: 10; or
- (xi) an amino acid sequence at least 99% identical to SEQ ID NO: 11, wherein the amino acid sequence of the polypeptide comprises no more than 5 amino acid substitutions relative to SEQ ID NO: 11.

2. The influenza HA polypeptide of claim **1**, comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.

3. A composition comprising the influenza HA polypeptide of claim **1**, and a pharmaceutically acceptable carrier.

4. A method of eliciting an immune response to influenza virus in a subject, comprising administering the composition of claim **3** to the subject.

5. The method of claim 4, wherein the composition further comprises an adjuvant.

6. The method of claim 4, wherein the composition is administered intramuscularly.

* * * * *